"container.title","created","deposited","published.online","doi","indexed","issued","member","prefix","publisher","score","source","reference.count","references.count","is.referenced.by.count","title","type","url","language","author","link","reference","abstract","alternative.id","issn","page","update.policy","short.container.title","license","published.print","issue","volume","subtitle","archive","isbn"
"Definitions","2019-08-09","2023-10-04","2019-08-09","10.32388/668828","2024-09-11","2019-08-09","17262","10.32388","Qeios","20.67504","Crossref","1","1","0","Bias","reference-entry","http://dx.doi.org/10.32388/668828","en","John P. A.; Ioannidis; first","https://www.qeios.com/read/668828/pdf; https://www.qeios.com/read/668828/pdf; application/pdf; unspecified; vor; vor; unspecified; similarity-checking","ref1; publisher; 10.1371/journal.pmed.0020124",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Cochrane Database of Systematic Reviews","2005-07-04","2021-08-09","2005-07-20","10.1002/14651858.cd005064.pub2","2024-09-19","2005-07-20","311","10.1002","John Wiley & Sons, Ltd","19.66225","Crossref","157","157","32","Anticonvulsants for alcohol withdrawal","reference-entry","http://dx.doi.org/10.1002/14651858.cd005064.pub2","en","Anastasia; Panagiotis; John PA; Despina; Polycarpou; Papanikolau; Ioannidis; Contopoulos Ioannidis; first; additional; additional; additional","https://onlinelibrary.wiley.com/doi/full/10.1002/14651858.CD005064.pub2; unspecified; vor; similarity-checking","3; 6; NA; 5; 1; 5; 1; 3; 3; 5; 5; NA; 5; NA; 2; 2; NA; NA; 1-2; 2; 3; 2-3; 2; 2; 527; 5; 5; 2; 3; 3; 1; 1; 1-2; 3; 9; 3; 1; 3; 12; 10; 13; 1; 3; NA; 2; NA; 1164; 2; 5; 5; 4; 3; 3-4; 10; NA; 7; 3; 3; 4; 5; 3; 8652; 1; 6; 2; 3; 39; 6; 3; 4; 4; 5; 6; NA; NA; 3B; 5; 3; NA; 5; 4; NA; 3; 1; 6; 2; 9370; 9; 0; 1; 5; 4; 5; 1; 3; 9; 15; 1; 4; 2; NA; 5; 6; 5; 2; 1; 4; 4; 3; 1; 7; 2; NA; 33; 8; NA; 25; 3; 9; 4; 3; NA; 42; 5; 1; 6; 5; 5; 6; 9370; 1; 14; 2; NA; 51; NA; 11; 1-2; 9013; 2; NA; NA; NA; 3; 5-6; 2; 11; 11; 1-2; 5335; 2; 24; NA; 2; 5; 3; 3; 10.1002/14651858.CD005064.pub2-BIB1|cit1; 10.1002/14651858.CD005064.pub2-BIB2|cit2; 10.1002/14651858.CD005064.pub2-BIB3|cit3; 10.1002/14651858.CD005064.pub2-BIB4|cit4; 10.1002/14651858.CD005064.pub2-BIB5|cit5; 10.1002/14651858.CD005064.pub2-BIB6|cit6; 10.1002/14651858.CD005064.pub2-BIB7|cit7; 10.1002/14651858.CD005064.pub2-BIB8|cit8; 10.1002/14651858.CD005064.pub2-BIB9|cit9; 10.1002/14651858.CD005064.pub2-BIB10|cit10; 10.1002/14651858.CD005064.pub2-BIB11|cit11; 10.1002/14651858.CD005064.pub2-BIB12|cit12; 10.1002/14651858.CD005064.pub2-BIB13|cit13; 10.1002/14651858.CD005064.pub2-BIB14|cit14; 10.1002/14651858.CD005064.pub2-BIB15|cit15; 10.1002/14651858.CD005064.pub2-BIB16|cit16; 10.1002/14651858.CD005064.pub2-BIB17|cit17; 10.1002/14651858.CD005064.pub2-BIB18|cit18; 10.1002/14651858.CD005064.pub2-BIB19|cit19; 10.1002/14651858.CD005064.pub2-BIB20|cit20; 10.1002/14651858.CD005064.pub2-BIB21|cit21; 10.1002/14651858.CD005064.pub2-BIB22|cit22; 10.1002/14651858.CD005064.pub2-BIB23|cit23; 10.1002/14651858.CD005064.pub2-BIB24|cit24; 10.1002/14651858.CD005064.pub2-BIB25|cit25; 10.1002/14651858.CD005064.pub2-BIB26|cit26; 10.1002/14651858.CD005064.pub2-BIB27|cit27; 10.1002/14651858.CD005064.pub2-BIB28|cit28; 10.1002/14651858.CD005064.pub2-BIB29|cit29; 10.1002/14651858.CD005064.pub2-BIB30|cit30; 10.1002/14651858.CD005064.pub2-BIB31|cit31; 10.1002/14651858.CD005064.pub2-BIB32|cit32; 10.1002/14651858.CD005064.pub2-BIB33|cit33; 10.1002/14651858.CD005064.pub2-BIB34|cit34; 10.1002/14651858.CD005064.pub2-BIB35|cit35; 10.1002/14651858.CD005064.pub2-BIB36|cit36; 10.1002/14651858.CD005064.pub2-BIB37|cit37; 10.1002/14651858.CD005064.pub2-BIB38|cit38; 10.1002/14651858.CD005064.pub2-BIB39|cit39; 10.1002/14651858.CD005064.pub2-BIB40|cit40; 10.1002/14651858.CD005064.pub2-BIB41|cit41; 10.1002/14651858.CD005064.pub2-BIB42|cit42; 10.1002/14651858.CD005064.pub2-BIB43|cit43; 10.1002/14651858.CD005064.pub2-BIB44|cit44; 10.1002/14651858.CD005064.pub2-BIB45|cit45; 10.1002/14651858.CD005064.pub2-BIB46|cit46; 10.1002/14651858.CD005064.pub2-BIB47|cit47; 10.1002/14651858.CD005064.pub2-BIB48|cit48; 10.1002/14651858.CD005064.pub2-BIB49|cit49; 10.1002/14651858.CD005064.pub2-BIB50|cit50; 10.1002/14651858.CD005064.pub2-BIB51|cit51; 10.1002/14651858.CD005064.pub2-BIB52|cit52; 10.1002/14651858.CD005064.pub2-BIB53|cit53; 10.1002/14651858.CD005064.pub2-BIB54|cit54; 10.1002/14651858.CD005064.pub2-BIB55|cit55; 10.1002/14651858.CD005064.pub2-BIB56|cit56; 10.1002/14651858.CD005064.pub2-BIB57|cit57; 10.1002/14651858.CD005064.pub2-BIB58|cit58; 10.1002/14651858.CD005064.pub2-BIB59|cit59; 10.1002/14651858.CD005064.pub2-BIB60|cit60; 10.1002/14651858.CD005064.pub2-BIB61|cit61; 10.1002/14651858.CD005064.pub2-BIB62|cit62; 10.1002/14651858.CD005064.pub2-BIB63|cit63; 10.1002/14651858.CD005064.pub2-BIB64|cit64; 10.1002/14651858.CD005064.pub2-BIB65|cit65; 10.1002/14651858.CD005064.pub2-BIB66|cit66; 10.1002/14651858.CD005064.pub2-BIB67|cit67; 10.1002/14651858.CD005064.pub2-BIB68|cit68; 10.1002/14651858.CD005064.pub2-BIB69|cit69; 10.1002/14651858.CD005064.pub2-BIB70|cit70; 10.1002/14651858.CD005064.pub2-BIB71|cit71; 10.1002/14651858.CD005064.pub2-BIB72|cit72; 10.1002/14651858.CD005064.pub2-BIB73|cit73; 10.1002/14651858.CD005064.pub2-BIB74|cit74; 10.1002/14651858.CD005064.pub2-BIB75|cit75; 10.1002/14651858.CD005064.pub2-BIB76|cit76; 10.1002/14651858.CD005064.pub2-BIB77|cit77; 10.1002/14651858.CD005064.pub2-BIB78|cit78; 10.1002/14651858.CD005064.pub2-BIB79|cit79; 10.1002/14651858.CD005064.pub2-BIB80|cit80; 10.1002/14651858.CD005064.pub2-BIB81|cit81; 10.1002/14651858.CD005064.pub2-BIB82|cit82; 10.1002/14651858.CD005064.pub2-BIB83|cit83; 10.1002/14651858.CD005064.pub2-BIB84|cit84; 10.1002/14651858.CD005064.pub2-BIB85|cit85; 10.1002/14651858.CD005064.pub2-BIB86|cit86; 10.1002/14651858.CD005064.pub2-BIB87|cit87; 10.1002/14651858.CD005064.pub2-BIB88|cit88; 10.1002/14651858.CD005064.pub2-BIB89|cit89; 10.1002/14651858.CD005064.pub2-BIB90|cit90; 10.1002/14651858.CD005064.pub2-BIB91|cit91; 10.1002/14651858.CD005064.pub2-BIB92|cit92; 10.1002/14651858.CD005064.pub2-BIB93|cit93; 10.1002/14651858.CD005064.pub2-BIB94|cit94; 10.1002/14651858.CD005064.pub2-BIB95|cit95; 10.1002/14651858.CD005064.pub2-BIB96|cit96; 10.1002/14651858.CD005064.pub2-BIB97|cit97; 10.1002/14651858.CD005064.pub2-BIB98|cit98; 10.1002/14651858.CD005064.pub2-BIB99|cit99; 10.1002/14651858.CD005064.pub2-BIB100|cit100; 10.1002/14651858.CD005064.pub2-BIB101|cit101; 10.1002/14651858.CD005064.pub2-BIB102|cit102; 10.1002/14651858.CD005064.pub2-BIB103|cit103; 10.1002/14651858.CD005064.pub2-BIB104|cit104; 10.1002/14651858.CD005064.pub2-BIB105|cit105; 10.1002/14651858.CD005064.pub2-BIB106|cit106; 10.1002/14651858.CD005064.pub2-BIB107|cit107; 10.1002/14651858.CD005064.pub2-BIB108|cit108; 10.1002/14651858.CD005064.pub2-BIB109|cit109; 10.1002/14651858.CD005064.pub2-BIB110|cit110; 10.1002/14651858.CD005064.pub2-BIB111|cit111; 10.1002/14651858.CD005064.pub2-BIB112|cit112; 10.1002/14651858.CD005064.pub2-BIB113|cit113; 10.1002/14651858.CD005064.pub2-BIB114|cit114; 10.1002/14651858.CD005064.pub2-BIB115|cit115; 10.1002/14651858.CD005064.pub2-BIB116|cit116; 10.1002/14651858.CD005064.pub2-BIB117|cit117; 10.1002/14651858.CD005064.pub2-BIB118|cit118; 10.1002/14651858.CD005064.pub2-BIB119|cit119; 10.1002/14651858.CD005064.pub2-BIB120|cit120; 10.1002/14651858.CD005064.pub2-BIB121|cit121; 10.1002/14651858.CD005064.pub2-BIB122|cit122; 10.1002/14651858.CD005064.pub2-BIB123|cit123; 10.1002/14651858.CD005064.pub2-BIB124|cit124; 10.1002/14651858.CD005064.pub2-BIB125|cit125; 10.1002/14651858.CD005064.pub2-BIB126|cit126; 10.1002/14651858.CD005064.pub2-BIB127|cit127; 10.1002/14651858.CD005064.pub2-BIB128|cit128; 10.1002/14651858.CD005064.pub2-BIB129|cit129; 10.1002/14651858.CD005064.pub2-BIB130|cit130; 10.1002/14651858.CD005064.pub2-BIB131|cit131; 10.1002/14651858.CD005064.pub2-BIB132|cit132; 10.1002/14651858.CD005064.pub2-BIB133|cit133; 10.1002/14651858.CD005064.pub2-BIB134|cit134; 10.1002/14651858.CD005064.pub2-BIB135|cit135; 10.1002/14651858.CD005064.pub2-BIB136|cit136; 10.1002/14651858.CD005064.pub2-BIB137|cit137; 10.1002/14651858.CD005064.pub2-BIB138|cit138; 10.1002/14651858.CD005064.pub2-BIB139|cit139; 10.1002/14651858.CD005064.pub2-BIB140|cit140; 10.1002/14651858.CD005064.pub2-BIB141|cit141; 10.1002/14651858.CD005064.pub2-BIB142|cit142; 10.1002/14651858.CD005064.pub2-BIB143|cit143; 10.1002/14651858.CD005064.pub2-BIB144|cit144; 10.1002/14651858.CD005064.pub2-BIB145|cit145; 10.1002/14651858.CD005064.pub2-BIB146|cit146; 10.1002/14651858.CD005064.pub2-BIB147|cit147; 10.1002/14651858.CD005064.pub2-BIB148|cit148; 10.1002/14651858.CD005064.pub2-BIB149|cit149; 10.1002/14651858.CD005064.pub2-BIB150|cit150; 10.1002/14651858.CD005064.pub2-BIB151|cit151; 10.1002/14651858.CD005064.pub2-BIB152|cit152; 10.1002/14651858.CD005064.pub2-BIB153|cit153; 10.1002/14651858.CD005064.pub2-BIB154|cit154; 10.1002/14651858.CD005064.pub2-BIB155|cit155; 10.1002/14651858.CD005064.pub2-BIB156|cit156; 10.1002/14651858.CD005064.pub2-BIB157|cit157; 160; 645; 131; 333; 159; 514; 12; 263; 263; 520; 395; A17; 398; 121; 99; 99; 1065; 1; 49; 174; 213; 127; 55; 168; 1191; 617; 349; 141; 238; 227; 155; 67; 55; 513; 1324; 254; 95; 189; 1381; 1430; 533; 43; 414; 5; 153; NA; 1141; 175; 581; 504; 873; 132; 183; 528; 167; 712; 156; 120; 321; 277; 323; 1435; 23; 331; 176; 651; 3109; 617; 738; 185; 277; 721; 1174; 401; 60; 30; 413; 321; 453; 354; 641; 1137; 223; 27; 511; 109; 1677; 905; 685; 94; 542; 415; 426; 92; 263; 1534; 905; 1; 377; 302; 177; 291; 1007; 172; 90; 86; 205; 495; 269; 1; 1041; 175; S397; 899; 673; 21; 493; 249; 778; 515; 168; S50; 947; 481; 52; 734; 611; 369; 544; 1666; 37; 420; 202; 316; 9304; 144; 436; 19; 1438; 230; 51; 619; 81; 189; 509; 163; 1537; 1054; 79; 52; 144; 1962; 114; 277; 408; 289; 332; Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride; Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures; Treatment of alcohol abstinence symptoms with the alpha 2-agonist clonidine; Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal Multicentre double-blind comparison with placebo; Atrium 300 and Alcohol Withdrawal: Double-Blind Placebo-Controlled Study in 38 hospitalized patients; Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-centre trial; Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents; Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms; Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms; Emergency department treatment of alcohol withdrawal seizures with phenytoin; Piracetam and chlormethiazole in acute alcohol withdrawal: a controlled clinical trial; Randomized controlled trial for the treatment of alcohol withdrawal syndrome: clome gamma-hydroxybutyric acid abstract; Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal); Evaluation of chlormethiazole in treatment for alcohol withdrawal syndrome. Results of a controlled trial; Comparative evaluation of treatments of alcohol withdrawal syndromes; Comparative evaluation of treatments of alcohol withdrawal syndromes; Treatment of Delirium Tremens: A Comparative Evaluation of Four Drugs; Double-Blind Comparative Trial with Carbamazepine vs Diazepam Treatment of Alcohol Withdrawal; Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal--caroverine versus meprobamate in a randomised double-blind study; Delirium tremens: a double-blind comparison of diazepam and barbital treatment; Sodium valproate in the treatment of the alcohol withdrawal syndrome; Comparison of chlormethiazole (Heminevrin) and chlordiazepoxide (Librium) in the treatment of acute alcohol withdrawal; Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention; Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam; Chlormethiazole and trifluoperazine in alcohol withdrawal; Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal; The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomised trial; The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification; Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms; Tiapride and chlormethiazole in alcohol withdrawal: A double-blind trial; Divalproex in the treatment of alcohol withdrawal; Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal; Double blind study on the efficacy and safety of tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome; The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures; Divalproex sodium in alcohol withdrawal: a randomised double-blind placebo-controlled clinical trial; A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome; Is clonidine useful in the treatment of alcohol withdrawal?; A pilot open randomised trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal; Prevention of alcohol withdrawal seizures: the roles of diphenylhydantoin and chlordiazepoxide; Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study; [Double-blind study of the efficacy of tetrabamate and tiapride in the treatment of alcohol deprivation syndrome]; Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance-a pilot study; Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial; The use of carbamazepine in chormethiazole-modified withdrawal from alcohol; Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study; NA; A double-blind comparative study of atrium 300 and heminiurine in chronic alcoholics; Diazepam and paraldehyde for treatment of severe delirium tremens. A controlled trial; Alprazolam versus chlormethiazole in acute alcohol withdrawal; Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study; Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings; An open study with acamprosate in Belgium and Luxemburg: results on socio demographics, supportive treatment and outcome; [Criteria of the efficacy of therapeutic measures in alcoholic delirium. Study on the effectiveness of aprotinin in alcoholic delirium]; [Comparison of the effectiveness of neuroleptics and chlormethiazol in the treatment of alcoholic delirium (author's translation)]; Comparative investigation of chlormethiazole and neuroleptic agents in the treatment of alcoholic delirium; Alpha-2-adrenoceptor sensitivity in early alcohol withdrawal; Efficacy of acamprosate in the treatment of alcohol-dependent outpatients; Comparative study with Grandaxin and diazepam in alcohol withdrawal syndrome and gerontopsychiatric diseases; A double-blind crossover comparison between clothiapine and diazepam in the treatment of mental symptoms in chronic alcoholics; [Clinical trial of Tegretol and Anafranil/Sinequan in alcohol abstinence symptoms]; The use of divalproex in alcohol relapse prevention: a pilot study; Controlled trial of acupuncture for severe recidivist alcoholism; [Treatment of delirium tremens--a comparison between clomethiazole and clorazepate with reference to effectiveness and rate of side effects]; [Prevention and therapy of delirium tremens with tiapride and chlordesmethyldiazepam]; United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol; Adrenergic agonist therapy in alcohol withdrawal states in man; Trial of tiapride in patients discharged after hospitalization for alcohol withdrawal. A randomized, double-blind trial in fifty-one patients with alcohol related liver disease; Autonomic reactivity to mental stressors after single administration of lorazepam in male alcoholics and healthy controls; Intrathecal and oral clonidine as prophylaxis for postoperative alcohol withdrawal syndrome: a randomized double-blinded study; Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study; Nonpharmacological supportive care compared to chlormethiazole infusion in the management of severe acute alcohol withdrawal; Improvements in treatment of alcohol withdrawal syndromes; One more look at carbamazepine in the treatment of alcohol withdrawal; Controlled trial of chlormethiazole in treatment of the alcoholic withdrawal phase; Slow-release Carbamazepine for Therapy of Alcoholic Predelirium- Results of a Double-blind Clinical Trial using Timonol 150 retard; Investigation of the abuse liability of buspirone in alcohol-dependent patients; Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain; Efficacy of tiapride in the maintenance of abstinence in weaned alcoholics. Results of a double-blind trial against placebo.; Comparison of the behavioral effects and abuse liability of ethanol and pentobarbital in recreational sedative abusers; Post-detoxification drug treatment of anxiety and depression in alcohol addicts; Controlled trial comparing amobarbital and clomethiazole in alcohol withdrawal symptoms; [Alcohol withdrawal syndrome in the postoperative phase--therapy or prevention?]; Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid; Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol; Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism; Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics; Oral topiramate for treatment of alcohol dependence: a randomised controlled trial; Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial; Prevention of delirium tremens: use of phenothiazines versus drugs cross-dependent with alcohol; Phenytoin, Metronidazole and multivitamins in the treatment of alcoholism; Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients; Acupuncture in the treatment of alcohol withdrawal symptoms: a randomized, placebo-controlled inpatient study; A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: lofexidine is not a useful adjunct to chlordiazepoxide; Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study; Barbital and diazepam plasma levels during treatment of delirium tremens; Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics; Randomized clinical trial of atenolol in patients with alcohol withdrawal; Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis; Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations; Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity; Experience with three drugs in ambulatory treatment of alcohol patients; [Anxiolytic efficacy and tolerance of tetrabamate in anxious patients abusing alcohol. Multicenter double-blind versus placebo study]; A placebo-controlled trial of buspirone in anxious inpatient alcoholics; Halazepam in the management of acute alcohol withdrawal syndrome; A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics; A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence; A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism; A comparison of three approaches to alcohol-withdrawal states; Variations in response to citalopram in men and women with alcohol dependence; Trends in the management of alcohol withdrawal syndrome; Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype; Phenobarbital for alcohol withdrawal syndrome; Copmarison between gabapentine and acampronsate in the treatment of alcohol dependence patients; [Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management]; Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence; Relapse prevention in alcoholics with an anti craving drug treatment: first results of the Berlin Study; [Therapy of pre-delirium alcohol withdrawal syndrome. Results of a comparative study of carbamazepine and clomethiazole]; Changes in EEG, blood levels, mood scales and performance scores during long term treatment with diazepam, phenobarbital or placebo in patients; Carbamazepine effective for alcohol withdrawal; Tiapride in the prevention of relapse in recently detoxified alcoholics; Finnish experiences with carbamazepine (Tegretol) in the treatment of acute withdrawal symptoms in alcoholics; Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone; [Piracetam in the treatment of alcohol-induced delirium]; [Comparative evaluation of the effectiveness of various methods of treating delirium tremens]; Double-blind comparison of lorazepam and chlordiazepoxide in the treatment of the acute alcohol abstinence syndrome; Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection; Reduction in early alcohol abstinence fits by administration of carbamazepine syrup instead of tablets; Carbamazepine and physostigmine eyedrops in the treatment of early alcohol withdrawal and alcohol-related hypertension; Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials; Topiramate for the treatment of alcohol dependence: initiating abstinence; [Double-blind study of Aprotininum (Trasylol) in the management of alcoholic delirium]; [A comparative double-blind study of atrium 300 and hemineurine in chronic alcoholics (author's transl)]; Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study; Treatment of the Alcohol Withdrawal Syndrome. Comparison of Promazine and Paraldehyde; New type of treatment for alcohol withdrawal syndrome; Clonidine versus chlomethiazole in alcohol withdrawal; Chlordiazepoxide (librium) compared with meprobamate and promazine (prozine) for the withdrawal symptoms of acute alcoholism; [Clomethiazole (chloromethiazole) in the treatment of delirium tremens]; Comparison of acamprosate and placebo in long-term treatment of alcohol dependence; Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group; Slow-release carbamazepine for therapy of alcoholic predelirium: Results of a double blind clinical trial using Timonil 150 retard; A comparison of promazine and paraldehyde in 175 cases of alcohol withdrawal; A controlled trial of chlormethiazole and chlordiazepoxide in the treatment of the acute withdrawal phase of alcoholism; Alcohol and withdrawal: from animal research to clinical issues; Glutamate-mediated transmission, alcohol, and alcoholism; Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics; The natural history of alcohol abuse: implications for definitions of alcohol use disorders; The hazards of scoring the quality of clinical trials for meta-analysis; Ethanol and negative feedback regulation of mesolimbic dopamine release in rats; Drug abuse: hedonic homeostatic dysregulation; Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal; Meta-analysis of randomised controlled trials: a concern for standards; Alcohol and the brain. Pharmacological insights for psychiatrists; Plasma gamma-aminobutyric acid (GABA) is low in alcoholics; Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials; Effects of chronic ethanol exposure on neurophysiological responses to corticotropin-releasing factor and neuropeptide Y; The glutamatergic basis of human alcoholism; 10; 87; 327; 53; 17; 23; 88; 20; 20; 20; 6; 26 S; 69; 192; 201; 201; 33; 6 Suppl 3; 17; 58; 14; 10; 21; 38; 115; 146; 17; 11; 9; 18; 26; 37; 13; 23; 25; 64; 13; 7; 130; 230; 85; 9; 24; 8; 27; NA; 33; 82; 83; 37; 18; 6; 9; 48; 329; 31; 25; 31; 9; 100; 67; 1; 19; 52; 35; 21; 62; 35; 98; 251; 2; 13; 16; 2; 22; 80; 36; 14; 95; 162; 28; Supplement II; 6; 155; 12; 11; 361; 61; 9; 33; 57; 7; 36; 60; 59; 20; 313; 9; 23; 28; 192; 12; 16; 46; 19; 21; 11; 62; 25; 105; 24; 56; 12 Suppl 3; 126; 53; 27 Suppl 1; 105; 6; 51; 165; 7; 28 Suppl 3; 125; 14; 6; 75; 24; 21; 36; 361; 10; 65; 35; 188; 27; 327; 64; 16; 347; 23; 5; 38; 70 Suppl 1; 27; 37; 40; 147; 282; 139; 278; 278; 274; 175; 29; 273; 34; 152; Agricola; Alldredge; Balldin; Bjorkqvist; Blanchard; Bonnet; Borg; Burroughs; Burroughs; Chance; Dencker; Elsing; Flygenring; Glatt; Golbert; Golbert; Kaim; Kalyoncu; Koppi; Kramp; Lambie; Lapierre; Longo; Lucht; Madden; Malcolm; Malcolm; Malcolm; Manhem; Murphy; Myrick; Nimmerrichter; Radouco-Thomas; Rathlev; Reoux; Ritola; Robinson; Rosenthal; Rothstein; Sampliner; Santo Domingo Carrasco; Seifert; Spies; Stanhope; Stuppaeck; NA; Teijeiro; Thompson; Tubridy; Addolorato; Adinoff; Ansoms; Athen; Athen; Athen; Balldin; Baltieri; Banki; Block; Borg; Brady; Bullock; Caspari; Cazzato; Chick; Cushman; Delamaire; Demmel; Dobrydnjov; Franz; Frecker; Gallant; Gallant; Glatt; Gottesleben; Griffith; Gual; Gual; Guarino; Hague; Harfst; Heil; Hillbom; Hutchison; Ilyuchina; Janiri; Johnson; Johnson; Kaim; Kaplan; Karam-Hage; Karst; Keaney; Kiefer; Kramp; Kranzler; Kraus; Lange-Asschenfeldt; Bon; Fauve; Leivonen; Loo; Malcolm; Mendels; Miller; Mueller; Mukherjee; Muller; Naranjo; Newman; Pettinati; Rodgers; Rubio; Rychlik; Sass; Schmidt; Schulte; Schwarz; See; Shaw; Sillanpaa; Smith; Snel; Sobcyzk; Solomon; Spies; Sternebring; Stojek; Streeton; Swift; Tacke; Teijeiro; Tempesta; Thomas; Tress; Wadstein; Wegner; Welbel; Whitworth; Wiesbeck; Gottesleben; Hart; McGrath; Witte; Dodd; Gilman; Hasin; Juni; Kohl; Koob; Mayo-Smith; Moher; Nutt; Petty; Schulz; Slawecki; Tsai; 1982; 1989; 1986; 1976; 1985; 2003; 1986; 1985; 1985; 1991; 1978; 1996; 1984; 1966; 1967; 1967; 1972; 1996; 1987; 1978; 1980; 1983; 2002; 2003; 1969; 1989; 2002; 2002; 1985; 1983; 2000; 2002; 1989; 1994; 2001; 1981; 1989; 1998; 1973; 1974; 1985; 2004; 1996; 1989; 1992; NA; 1975; 1975; 1988; 2002; 1994; 2000; 1976; 1977; 1986; 1992; 2003; 1983; 1974; 1980; 2002; 1989; 1992; 1982; 2000; 1985; 1986; 2000; 2004; 2001; 1982; 1989; 1992; 1965; 1995; 1986; 2001; 2002; 1989; 1976; 1967; 1990; 1989; 2001; 1995; 1996; 2003; 2004; 1974; 1972; 2003; 2002; 2001; 2003; 1979; 1996; 1985; 2003; 2003; 2004; 1966; 1986; 1992; 1985; 1988; 1997; 1983; 1969; 2000; 1995; 2000; 1999; 2002; 2001; 1996; 1994; 1987; 1982; 2002; 1994; 1979; 1987; 1983; 1980; 1983; 1995; 1983; 1987; 2001; 2003; 1975; 1976; 2000; 1964; 1977; 1986; 1965; 1982; 1996; 1999; 1994; 1964; 1975; 2003; 2000; 1996; 1990; 1999; 1998; 1997; 1997; 1995; 1999; 1993; 1995; 1999; 1995; Journal of Internal Medical Research; American Journal of Medicine; Acta Psychiatrica Scandinavica Supplementum; Acta Psychiatrica Scandinavica; Psychological Medicine (Paris); Journal of Clinical Psychopharmacology; Psychopharmacology (Berlin); Alcohol and Alcoholism; Alcohol and Alcoholism; Annals of Emergency Medicine; Journal of Internal Medical Research; European Journal of Clinical Investigation; Acta Psychiatrica Scandinavica; Acta Psychiatrica Scandinavica Supplementum; Journal of the American Medical Association; Journal of the American Medical Association; Quarterly Journal of Studies on Alcohol; European Neuropsychopharmacology; Neuropsychobiology; Acta Psychiatrica Scandinavica; Australian and New Zeland Journal of Psychiatry; Neuropsychobiology; Journal of Addictive Diseases; Alcohol and Alcoholism; British Journal of Psychiatry; American Journal of Psychiatry; Journal of General Internal Medicine; American Journal on Addictions; Alcoholism, Clinical and Experimental Research; Alcohol and Alcoholism; American Journal of Drug and Alcohol Abuse; Alcohol and Alcoholism; Progress in Neuro-Psychopharmacology & Biological Psychiatry; Annals of Emergency Medicine; Alcoholism, Clinical and Experimental Research; Acta Psychiatrica Scandinavica; Alcoholism, Clinical and Experimental Research; American Journal on Addictions; American Journal of Psychiatry; Journal of the American Medical Association; Medicina Clinica (Barcelona); Addiction Biology; Critical Care Medicine; Australian Drug and Alcohol Review; Alcohol and Alcoholism; NA; Medicine et Hygiene (Geneve); Annals of Internal Medicine; British Journal of Addiction; Alcohol and Alcoholism; Alcoholism, Clinical and Experimental Research; European Addiction Research; Psychiatria Clinica; Nervenarzt (Berlin); Acta Psychiatrica Scandinavica Supplementum; Biological Psychiatry; Revista Brasileira de Psiquiatria; Therapia Hungarica; International Journal of Clinical Pharmacology; Tidsskrift for den Norske Laegeforening; Drug and Alcohol Dependence; The Lancet; Psychiatrische Praxis; Rivista di Neurologia; Alcohol and Alcoholism; Psychopharmacology Bulletin; La semaine des hopitaux: organe fonde par l' Association d' enseignement medical des hopitaux de Paris; Alcohol and Alcoholism; Anesthesia and Analgesia; European Archives of Psychiatry and Clinical Neuroscience; Journal of Clinical Psychopharmacology; Alcoholism, Clinical and Experimental Research; Alcoholism, Clinical and Experimental Research; British Medical Journal; Aktuelle Neurologie; American Journal of Medicine; Alcohol and Alcoholism; Adicciones; NIDA Research Monograph; Journal of Nervous and Mental Disease; Quarterly Journal of Studies on Alcohol; Langenbecks Archiv Fur Chirurgie, Verhandlungen der Deutschen Gesellschaft Chirurgie; Alcohol; Psychopharmacology (Berlin); Alcohol; International Clinical Psychopharmacology; The Lancet; Archives of General Psychiatry; Advances in Biochemical Psychopharmacology; Quarterly Journal of Studies on Alcohol; Psychiatry and Clinical Neurosciences; Addiction Biology; Alcohol and Alcoholism; Archives of General Psychiatry; Acta Psychiatrica Scandinavica; Alcoholism, Clinical and Experimental Research; The New England Journal of Medicine; European Addiction Research; Journal of Clinical Psychopharmacology; Alcoholism, Clinical and Experimental Research; Acta Psychiatrica Scandinavica Supplementum; L' encephale; Alcoholism, Clinical and Experimental Research; Journal of Clinical Psychiatry; Neuropsychobiology; Alcoholism, Clinical and Experimental Research; Journal of International Medical Research; Southern Medical Journal; Journal of Psychiatry & Neuroscience: JPN; The Laryngoscope; Alcoholism, Clinical and Experimental Research; American Journal of Health-System Pharmacy: AJHP; European Neuropsychopharmacology; Deutsche Medizinische Wochenschrift; Archives of General Psychiatry; Pharmacopsychiatry; Fortschritte der Medizin; Progress in Neuro-Psychopharmacology & Biological Psychiatry; The Journal of Family Practise; British Journal of Psychiatry; Journal of International Medical Research; Epilepsia; MMW. Munchener Medizinische Wochenschrift; Psychiatria Polska; Clinical Therapeutics; British Journal of Anaesthesia; European Journal Clinical Pharmacology; Psychiatria Polska; Alcohol and Alcoholism; The Lancet; International Pharmacopsychiatry; Schweizerische Rundschau fur Medizin Praxis; Alcohol and Alcoholism; Journal of the American Medical Association; TherapieWoche; Acta Psychiatrica Scandinavica Supplementum; Wisconsin Medical Journal; Psychiatria Polska; The Lancet; Alcoholism, Clinical and Experimental Research; European Journal of Clinical Research; Psychiatric Quarterly; British Journal of Addiction to Alcohol and Other Drugs; Neuroscience and Biobehavioral Reviews; Neurochemistry International; Annals of Neurology; The American Journal of Psychiatry; Journal of the American Medical Association; Psychopharmacology; Science; Journal of the American Medical Association; Journal of the American Medical Association; The British Journal of Psychiatry; Psychopharmacology Bulletin; Journal of the American Medical Association; Alcohol and Alcoholism; The American Journal of Psychiatry; NA; crossref; NA; crossref; NA; crossref; crossref; NA; NA; crossref; NA; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; NA; NA; NA; crossref; crossref; crossref; crossref; crossref; NA; NA; crossref; crossref; crossref; NA; NA; NA; crossref; crossref; NA; NA; crossref; NA; NA; crossref; crossref; crossref; crossref; NA; NA; crossref; crossref; crossref; crossref; NA; NA; crossref; crossref; NA; crossref; crossref; crossref; NA; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; NA; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; NA; crossref; crossref; crossref; NA; crossref; NA; crossref; crossref; crossref; NA; NA; NA; crossref; crossref; NA; crossref; crossref; crossref; NA; crossref; NA; NA; NA; NA; NA; crossref; NA; NA; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; NA; 10.1016/S0002-9343(89)80397-3; NA; 10.1111/j.1600-0447.1976.tb00081.x; NA; 10.1097/01.jcp.0000088905.24613.ad; 10.1007/BF00310506; NA; NA; 10.1016/S0196-0644(05)81606-3; NA; NA; 10.1111/j.1600-0447.1984.tb02511.x; 10.1111/j.1600-0447.1966.tb08822.x; 10.1001/jama.1967.03130020045009; 10.1001/jama.1967.03130020045009; 10.15288/qjsa.1972.33.1065; 10.1016/0924-977X(96)87301-9; 10.1159/000118340; 10.1111/j.1600-0447.1978.tb06930.x; 10.3109/00048678009159381; 10.1159/000117998; 10.1300/J069v21n02_05; 10.1093/alcalc/agg050; 10.1192/bjp.115.527.1191; 10.1176/ajp.146.5.617; 10.1007/s11606-002-0038-1; 10.1080/10550490290087910; 10.1111/j.1530-0277.1985.tb05743.x; NA; 10.1081/ADA-100100597; 10.1093/alcalc/37.1.67; 10.1016/0278-5846(89)90004-3; 10.1016/S0196-0644(94)70070-2; 10.1111/j.1530-0277.2001.tb02354.x; 10.1111/j.1600-0447.1981.tb00781.x; 10.1111/j.1530-0277.1989.tb00290.x; 10.3109/10550499808998350; 10.1176/ajp.130.12.1381; 10.1001/jama.1974.03240100048028; NA; 10.1080/13556210410001674086; 10.1097/00003246-199603000-00009; 10.1080/09595238980000021; NA; NA; NA; 10.7326/0003-4819-82-2-175; 10.1111/j.1360-0443.1988.tb02578.x; 10.1093/alcalc/37.5.504; 10.1111/j.1530-0277.1994.tb00053.x; 10.1159/000019025; NA; NA; 10.1111/j.1600-0447.1986.tb10556.x; 10.1016/0006-3223(92)90281-4; 10.1590/S1516-44462003000300007; NA; NA; NA; 10.1016/S0376-8716(02)00105-9; 10.1016/S0140-6736(89)90135-9; NA; NA; 10.1093/alcalc/35.2.176; NA; NA; 10.1093/alcalc/35.6.617; 10.1213/01.ANE.0000099719.97261.DA; 10.1007/s004060170039; 10.1097/00004714-198208000-00009; NA; NA; 10.1136/bmj.2.5458.401; 10.1055/s-2007-1017890; 10.1016/0002-9343(86)90329-3; 10.1093/alcalc/36.5.413; NA; NA; 10.1097/00005053-197605000-00006; 10.15288/qjsa.1967.28.641; NA; 10.1016/0741-8329(89)90022-0; 10.1007/s002130000629; 10.1016/0741-8329(95)00036-4; NA; 10.1016/S0140-6736(03)13370-3; 10.1001/archpsyc.61.9.905; NA; 10.15288/qjsa.1972.33.097; 10.1046/j.1440-1819.2003.01161.x; 10.1080/1355621021000006017; 10.1093/alcalc/36.5.426; 10.1001/archpsyc.60.1.92; 10.1111/j.1600-0447.1979.tb06966.x; 10.1111/j.1530-0277.1996.tb01696.x; 10.1056/NEJM198510103131501; 10.1159/000067729; 10.1097/01.jcp.0000085411.08426.d3; 10.1097/01.ALC.0000113413.37910.D7; 10.1111/j.1600-0447.1966.tb08831.x; NA; 10.1111/j.1530-0277.1992.tb00691.x; NA; 10.1159/000118441; 10.1111/j.1530-0277.1997.tb03733.x; 10.1177/030006058301100402; 10.1097/00007611-196904000-00031; NA; 10.1288/00005537-199501000-00004; 10.1111/j.1530-0277.2000.tb04648.x; 10.1093/ajhp/56.2.175; NA; 10.1055/s-2001-16502; 10.1001/archpsyc.1996.01830080023006; 10.1055/s-2007-1014321; NA; 10.1016/S0278-5846(82)80175-9; NA; 10.1192/bjp.165.4.515; 10.1177/030006057900700302; 10.1111/j.1528-1157.1987.tb05778.x; NA; NA; NA; 10.1093/bja/75.6.734; 10.1007/BF00542209; NA; 10.1093/alcalc/36.6.544; 10.1016/S0140-6736(03)13378-8; 10.1159/000468166; NA; 10.1093/alcalc/35.2.202; NA; NA; NA; NA; NA; 10.1016/S0140-6736(96)91682-7; NA; NA; NA; 10.1111/j.1360-0443.1975.tb01340.x; 10.1016/S0149-7634(03)00030-7; 10.1016/S0197-0186(00)00061-9; 10.1002/ana.410400207; 10.1176/ajp.147.11.1537; 10.1001/jama.282.11.1054; 10.1007/s002130050692; 10.1126/science.278.5335.52; 10.1001/jama.1997.03550020076042; 10.1001/jama.1995.03530240072044; 10.1192/bjp.175.2.114; NA; 10.1001/jama.1995.03520290060030; 10.1093/alcalc/34.3.289; 10.1176/ajp.152.3.332; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Stuppaeck C Whitworth A Deisenhammer E Honeder M Kurz M Telser S Vigabatrin in the Treatment of Alcohol Withdrawal Syndrome : a Double-Blind , Randomized Study XXIst Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland.12th-16th July, 1998 1998 PW13010; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NA,"2022-11-13","2024-04-23",NA,"10.1101/2022.11.11.22282231","2024-04-24","2022-11-13","246","10.1101","Cold Spring Harbor Laboratory","19.497156","Crossref","39","39","0","Transparency in infectious disease research: a meta-research survey of specialty journals","posted-content","http://dx.doi.org/10.1101/2022.11.11.22282231",NA,"http://orcid.org/0000-0001-6205-1362; http://orcid.org/0000-0002-1918-8918; http://orcid.org/0000-0003-3118-6859; FALSE; FALSE; FALSE; Emmanuel A.; Despina G.; John P.A.; Zavalis; Contopoulos-Ioannidis; Ioannidis; first; additional; additional","https://syndication.highwire.org/content/doi/10.1101/2022.11.11.22282231; unspecified; vor; similarity-checking","7882; NA; NA; 1; 28; NA; NA; NA; NA; NA; 10; 12; 3; 1; NA; NA; NA; 1; NA; 9; NA; NA; 1; NA; NA; NA; 1; NA; NA; 5; NA; NA; 1; NA; NA; NA; NA; 7934; 3; 2022111501450538000_2022.11.11.22282231v1.1; 2022111501450538000_2022.11.11.22282231v1.2; 2022111501450538000_2022.11.11.22282231v1.3; 2022111501450538000_2022.11.11.22282231v1.4; 2022111501450538000_2022.11.11.22282231v1.5; 2022111501450538000_2022.11.11.22282231v1.6; 2022111501450538000_2022.11.11.22282231v1.7; 2022111501450538000_2022.11.11.22282231v1.8; 2022111501450538000_2022.11.11.22282231v1.9; 2022111501450538000_2022.11.11.22282231v1.10; 2022111501450538000_2022.11.11.22282231v1.11; 2022111501450538000_2022.11.11.22282231v1.12; 2022111501450538000_2022.11.11.22282231v1.13; 2022111501450538000_2022.11.11.22282231v1.14; 2022111501450538000_2022.11.11.22282231v1.15; 2022111501450538000_2022.11.11.22282231v1.16; 2022111501450538000_2022.11.11.22282231v1.17; 2022111501450538000_2022.11.11.22282231v1.18; 2022111501450538000_2022.11.11.22282231v1.19; 2022111501450538000_2022.11.11.22282231v1.20; 2022111501450538000_2022.11.11.22282231v1.21; 2022111501450538000_2022.11.11.22282231v1.22; 2022111501450538000_2022.11.11.22282231v1.23; 2022111501450538000_2022.11.11.22282231v1.24; 2022111501450538000_2022.11.11.22282231v1.25; 2022111501450538000_2022.11.11.22282231v1.26; 2022111501450538000_2022.11.11.22282231v1.27; 2022111501450538000_2022.11.11.22282231v1.28; 2022111501450538000_2022.11.11.22282231v1.29; 2022111501450538000_2022.11.11.22282231v1.30; 2022111501450538000_2022.11.11.22282231v1.31; 2022111501450538000_2022.11.11.22282231v1.32; 2022111501450538000_2022.11.11.22282231v1.33; 2022111501450538000_2022.11.11.22282231v1.34; 2022111501450538000_2022.11.11.22282231v1.35; 2022111501450538000_2022.11.11.22282231v1.36; 2022111501450538000_2022.11.11.22282231v1.37; 2022111501450538000_2022.11.11.22282231v1.38; 2022111501450538000_2022.11.11.22282231v1.39; crossref; crossref; publisher; crossref; crossref; publisher; publisher; publisher; crossref; publisher; crossref; crossref; crossref; crossref; publisher; NA; publisher; crossref; NA; crossref; crossref; publisher; crossref; publisher; publisher; publisher; crossref; publisher; crossref; crossref; crossref; NA; crossref; publisher; publisher; crossref; NA; crossref; crossref; S9; NA; NA; 1; e2204074119; NA; NA; NA; 108782; NA; e0275380; 1229; 194; 943; NA; NA; NA; 6; NA; 210389; NA; NA; 136; NA; NA; NA; 174; NA; NA; 607; NA; NA; e0227045; NA; NA; 649; NA; 23; 297; 10.1038/d41586-021-02909-5; 10.1016/B978-012373944-5.00185-1; 10.1136/bmjgh-2022-008477; 10.1007/s12546-021-09271-3; 10.1073/pnas.2204074119; 10.1038/s41591-020-1015-0; 10.1371/journal.pone.0263001; 10.1126/science.aah6168; 10.1016/j.mbs.2022.108782; 10.1073/pnas.1708274114; 10.1371/journal.pone.0275380; 10.1001/jamadermatol.2017.3109; 10.1001/jamaoto.2017.2741; 10.1038/s41467-021-21220-5; 10.1136/bmjebm-2021-111710; NA; 10.1371/journal.pbio.3001107; 10.1038/s41562-017-0189-z; NA; 10.1098/rsos.210389; 10.1136/bmj.m982; 10.1371/journal.pbio.1002333; 10.1186/s12910-021-00701-8; 10.1371/journal.pone.0067111; 10.1038/d41586-022-00402-1; 10.1016/j.jclinepi.2015.05.029; 10.1186/s12916-019-1409-3; 10.1126/scitranslmed.3007513; 10.1136/bmj.c950; 10.1097/EDE.0b013e3181eafbcf; 10.1136/bmj.k3218; NA; 10.1371/journal.pone.0227045; 10.1136/jme.2008.026526; 10.1016/j.cmi.2019.07.025; 10.12688/f1000research.24136.1; NA; 10.1038/d41586-022-03418-9; 10.1016/S1473-3099(22)00070-6; The high burden of infectious disease; NA; NA; Loss of life expectancy due to respiratory infectious diseases: findings from the global burden of disease study in 195 countries and territories 1990-2017; Massive covidization of research citations and the citation elite; NA; NA; NA; Pre-registration of mathematical models; NA; A meta-epidemiological assessment of transparency indicators of infectious disease models; Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors; Evaluation of Industry Relationships Among Authors of Otolaryngology Clinical Practice Guidelines; Methodological quality of COVID-19 clinical research; NA; NA; NA; Redefine statistical significance; NA; The rapid, massive growth of COVID-19 authors in the scientific literature; NA; NA; Equitable data sharing in epidemics and pandemics; NA; NA; NA; Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis; NA; NA; NA; NA; NA; Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing; NA; NA; Open Access of COVID-19-related publications in the first quarter of 2020: a preliminary study based in PubMed; NA; COVID research is free to access — but for how long?; NA; 598; NA; NA; 39; 119; NA; NA; NA; 345; NA; 17; 153; 144; 12; NA; NA; NA; 2; NA; 8; NA; NA; 22; NA; NA; NA; 17; NA; NA; 21; NA; NA; 15; NA; NA; 9; NA; 611; 22; 2021; NA; NA; 2022; 2022; NA; NA; NA; 2022; NA; 2022; 2017; 2018; 2021; NA; NA; NA; 2018; NA; 2021; NA; NA; 2021; NA; NA; NA; 2019; NA; NA; 2010; NA; NA; 2020; NA; NA; 2020; NA; 2022; 2022; Nature; NA; NA; J Popul Res (Canberra); Proc Natl Acad Sci U S A; NA; NA; NA; Math Biosci; NA; PLoS ONE; JAMA Dermatol; JAMA Otolaryngol Head Neck Surg; Nat Commun; NA; NA; NA; Nat Hum Behav; NA; R Soc open sci; NA; NA; BMC Med Ethics; NA; NA; NA; BMC Med; NA; NA; Epidemiology; NA; NA; PLoS ONE; NA; NA; F1000Res; NA; Nature; The Lancet Infectious Diseases; NA; Michaud CM . Global Burden of Infectious Diseases. Encyclopedia of Microbiology. 2009;444–54.; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Journal Impact Factor - Journal Citation Reports [Internet]. Web of Science Group. [cited 2022 Sep 14]. Available from: https://clarivate.com/webofsciencegroup/solutions/journal-citation-reports/; NA; NA; R: The R Project for Statistical Computing [Internet]. [cited 2022 Mar 29]. Available from: https://www.r-project.org/; NA; Al-Durra M , Nolan RP , Seto E , Cafazzo JA . Prospective registration and reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations. BMJ. 2020 Apr 14;m982.; NA; NA; NA; NA; NA; NA; NA; Loder E , Groves T , MacAuley D. Registration of observational studies. BMJ. 2010 Feb 18;340(feb18 2):c950–c950.; NA; Goldacre B , DeVito NJ , Heneghan C , Irving F , Bacon S , Fleminger J , et al. Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource. BMJ. 2018 Sep 12;k3218.; Home | OpenPayments [Internet]. [cited 2022 Nov 8]. Available from: https://openpaymentsdata.cms.gov/; NA; NA; NA; NA; Chiarelli, Andrea , Loffreda, Lucia , Cox, Eleanor , Johnson, Rob , Ferguson, Christine , Vignola-Gagné, Etienne , et al. From intent to impact: Investigating the effects of open sharing commitments [Internet]. Zenodo; 2022 Jun [cited 2022 Nov 8]. Available from: https://zenodo.org/record/7003684; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; The Registration of Observational Studies—When Metaphors Go Bad; NA; NA; NA; NA; NA; NA; NA; NA; The Lancet Infectious Diseases. Transitioning to endemicity with COVID-19 research","<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Infectious diseases carry a large global burden and have implications for society at large. Therefore, reproducible, transparent research is extremely important. To assess the current state of transparency in this field, we investigated code sharing, data sharing, protocol registration, conflict of interest and funding disclosures in articles published in the most influential infectious disease journals.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We evaluated transparency indicators in the 5340 PubMed Central Open Access (PMC OA) articles published in 2019 or 2021 in the 9 most-cited specialty journals in infectious disease. We used a previously validated text-mining R package,<jats:italic>rtransparent</jats:italic>. The approach was manually validated for a random sample of 200 articles for which study characteristics were also extracted in detail. Main comparisons assessed 2019 versus 2021 articles, 2019 versus 2021 non-COVID-19 articles, and 2021 non-COVID-19 articles versus 2021 COVID-19 articles.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 5340 articles were evaluated (1860 published in 2019 and 3480 in 2021 (of which 1828 on COVID-19)). Text-mining identified code sharing in 98 (2%) articles, data sharing in 498 (9%), registration in 446 (8%), conflict of interest disclosures in 4209 (79%) and funding disclosures in 4866 (91%). There were substantial differences across the 9 journals in the proportion of articles fulfilling each transparency indicator: 1-9% for code sharing, 5-25% for data sharing, 1-31% for registration, 7-100% for conflicts of interest, and 65-100% for funding disclosures. There were no major differences between articles published in 2019 and non-COVID-19 articles in 2021. In 2021, non-COVID-19 articles had more data sharing (12%) than COVID-19 articles (4%). Validation-corrected imputed estimates were 3% for code sharing, 11% for data sharing, 8% for registrations, 79% for conflict of interest disclosures and 92% for funding disclosures.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Data sharing, code sharing, and registration are very uncommon in infectious disease specialty journals. Increased transparency is required.</jats:p></jats:sec>",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"BMJ","2016-12-16","2020-09-26","2016-12-16","10.1136/bmj.i6747","2022-03-30","2016-12-16","239","10.1136","BMJ","19.307932","Crossref","0","0","0","Authors’ reply to Pérol and colleagues","journal-article","http://dx.doi.org/10.1136/bmj.i6747","en","Lars G; Despina G; John P A; Hemkens; Contopoulos-Ioannidis; Ioannidis; first; additional; additional","http://data.bmj.org/tdm/10.1136/bmj.i6747; https://syndication.highwire.org/content/doi/10.1136/bmj.i6747; unspecified; unspecified; vor; vor; text-mining; similarity-checking",NA,NA,"10.1136/bmj.i6747","1756-1833","i6747","http://dx.doi.org/10.1136/crossmarkpolicy","BMJ","2016-12-16; tdm; 0; http://www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html",NA,NA,NA,NA,NA,NA
"BMJ","2015-09-25","2020-09-26","2015-09-24","10.1136/bmj.h4992","2022-03-29","2015-09-24","239","10.1136","BMJ","18.943472","Crossref","0","0","1","John Ioannidis: Uncompromising gentle maniac","journal-article","http://dx.doi.org/10.1136/bmj.h4992","en",NA,"http://data.bmj.org/tdm/10.1136/bmj.h4992; https://syndication.highwire.org/content/doi/10.1136/bmj.h4992; unspecified; unspecified; vor; vor; text-mining; similarity-checking",NA,NA,"10.1136/bmj.h4992","1756-1833","h4992","http://dx.doi.org/10.1136/crossmarkpolicy",NA,"2015-09-24; tdm; 0; http://www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html",NA,NA,NA,NA,NA,NA
"The Lancet","2005-04-09","2019-01-27",NA,"10.1016/s0140-6736(05)79825-1","2024-09-13","1998-11","78","10.1016","Elsevier BV","18.943098","Crossref","5","5","63","Reporting of safety data from randomised trials","journal-article","http://dx.doi.org/10.1016/s0140-6736(05)79825-1","en","John PA; Despina G; Ioannidis; Contopoulos-Ioannidis; first; additional","https://api.elsevier.com/content/article/PII:S0140673605798251?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0140673605798251?httpAccept=text/plain; text/xml; text/plain; vor; vor; text-mining; text-mining","10.1016/S0140-6736(05)79825-1_bib1; 10.1016/S0140-6736(05)79825-1_bib2; 10.1016/S0140-6736(05)79825-1_bib3; 10.1016/S0140-6736(05)79825-1_bib4; 10.1016/S0140-6736(05)79825-1_bib5; crossref; crossref; NA; crossref; crossref; 62; 431; NA; 2765; 1089; 10.1016/0197-2456(94)00031-W; 10.1016/S0197-2456(97)00097-4; NA; 10.1001/jama.1993.03500210065033; 10.1016/S0895-4356(97)00149-2; Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists; The relationship between study design, results, and reporting of randomized trials of HIV infection; Clinical efficacy of antiretroviral changes in HIV-infected patients with prior antiretroviral treatment; Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems; The impact of high risk patients on the results of clinical trials; 16; 18; NA; 269; 50; Moher; Ioannidis; Ioannidis; Kessler; Ioannidis; 1995; 1997; 1997; 1993; 1997; Controlled Clinical Trials; Control Clin Trials; Online J Curr Clin Trials; JAMA; J Clin Epidemiol",NA,"S0140673605798251","0140-6736","1752-1753",NA,"The Lancet","1998-11-01; tdm; 0; https://www.elsevier.com/tdm/userlicense/1.0/","1998-11","9142","352",NA,NA,NA
"Pediatric Drugs","2006-01-23","2019-03-21",NA,"10.2165/00148581-200305020-00001","2024-03-03","2003","297","10.1007","Springer Science and Business Media LLC","18.85837","Crossref","49","49","0","Acute Sinusitis in Children","journal-article","http://dx.doi.org/10.2165/00148581-200305020-00001","en","Despina G.; John P.A.; Joseph; Contopoulos-Ioannidis; Ioannidis; Lau; first; additional; additional",NA,"R1-1; R2-1; R3-1; R4-1; R5-1; R6-1; R7-1; R8-1; R9-1; R10-1; R11-1; R12-1; R13-1; R14-1; R15-1; R16-1; R17-1; R18-1; R19-1; R20-1; R21-1; R22-1; R23-1; R24-1; R25-1; R26-1; R27-1; R28-1; R29-1; R30-1; R31-1; R32-1; R33-1; R34-1; R35-1; R37-1; R38-1; R39-1; R40-1; R41-1; R42-1; R43-1; R44-1; R45-1; R46-1; R47-1; R48-1; R50-1; R51-1; crossref; crossref; crossref; crossref; NA; crossref; NA; crossref; NA; crossref; NA; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; 1209; 319; E57; 38; 543; 297; 795; 375; 64; 413; 83; 43; 547; 50; 21; 342; 244; 576; 301; 457; 598; 619; 269; 256; 93; 165; 288; 225; 23; 121; 41; 49; 139; 45; 749; 701; 798; 292; 1; 166; 632; 437; 1752; 619; 677; 239; 49; 829; 963; 10.1093/clinids/23.6.1209; 10.1056/NEJM199201303260507; 10.1542/peds.108.3.e57; 10.1179/joc.1997.9.1.38; NA; 10.1016/S0022-3476(84)81018-5; NA; 10.3109/00016487209128466; NA; 10.1177/030006058000800609; NA; 10.3109/inf.1972.4.issue-1.09; 10.1093/jac/38.3.547; 10.1159/000221971; 10.2165/00003495-198600323-00005; 10.1177/000992287000900611; NA; 10.1097/00006454-199607000-00003; 10.1016/0165-5876(82)90042-8; 10.1177/000992289603500905; 10.1016/S1081-1206(10)63223-1; 10.1542/peds.107.4.619; 10.1177/000992289903800503; 10.1007/s004050050234; NA; 10.1542/peds.109.1.165; 10.1007/BF02597398; 10.1023/A:1008883508462; 10.1016/S0165-5876(99)00201-3; NA; 10.1111/j.1365-2273.1977.tb01333.x; 10.1111/j.1365-2273.1992.tb00987.x; 10.1016/0165-5876(82)90089-1; 10.1016/S0022-3476(89)80599-2; 10.1056/NEJM198103263041302; 10.1111/j.1525-1497.2001.00429.x; 10.1542/peds.108.3.798; 10.1128/AAC.41.2.292; 10.1097/00006454-199901000-00002; 10.1542/peds.109.1.166; 10.1136/bmj.317.7159.632; 10.1001/jama.285.4.437; 10.1016/S0140-6736(05)79825-1; 10.1016/S0895-4356(02)00393-1; 10.1093/jac/48.5.677; 10.1542/peds.108.2.239; 10.1001/jama.286.1.49; 10.1097/00006454-200109000-00002; 10.1097/00006454-199810000-00041; 23; 326; 108; 9; 5; 104; 77; 74; 14; 8; 37; 4; 38; 23; 32; 9; 152; 15; 4; 35; 78; 107; 38; 257; 15; 109; 4; 8; 50; 52; 2; 17; 4; 114; 304; 16; 108; 41; 18; 109; 317; 285; 352; 55; 48; 108; 286; 20; 17; Gwaltney; Wald; Ioannidis; Ficnar; Careddu; Wald; Wald; Jeppesen; Simon; Hager; Helin; Nylen; Gurses; Herz; Puhakka; McLean; Aitken; Ueda; Revonta; McCormick; Barlan; Garbutt; Simon; Yilmaz; Simon; Karadag; Mulrow; Garbutt; Sacco; Kogutt; Watt-Boolsen; Van Buchem; Jannert; Glasier; Wald; Balk; NA; Doern; Dowell; Harris; de Ferranti; Ioannidis; Ioannidis; Ioannidis; Ioannidis; Takata; Schrag; Dagan; Bottenfield; 1996; 1992; 2002; 1997; 1993; 1984; 1986; 1972; 1997; 1980; 1982; 1972; 1996; 1977; 1986; 1970; 1998; 1996; 1982; 1996; 1997; 2001; 1999; 2000; 2000; 2002; 1989; 1999; 1999; 1973; 1977; 1992; 1982; 1989; 1981; 2001; 2001; 1997; 1999; 2002; 1998; 2001; 1998; 2002; 2001; 2001; 2001; 2001; 1998; Clin Infect Dis; N Engl J Med; Pediatrics; J Chemother; J Chemother; J Pediatr; Pediatrics; Acta Otolaryngol; Adv Ther; J Int Med Res; Helv Paediatr Acta; Scand J Infect Dis; J Antimicrob Chemother; Chemotherapy; Drugs; Clin Pediatr (Phila); Arch Pediatr Adolesc Med; Pediatr Infect Dis J; Int J Pediatr Otorhinolaryngol; Clin Pediatr (Phila); Allergy Asthma Immunol; Pediatrics; Clin Pediatr; Eur Arch Otorhinolaryngol; Int Pediatr; Pediatrics; J Gen Intern Med; Qual Life Res; Int J Pediatr Otorhinolaryngol; Pediatrics; Clin Otolaryngol; Clin Otolaryngol; Int J Pediatr Otorhinolaryngol; J Pediatr; N Engl J Med; J Gen Intern Med; Pediatrics; Antimicrob Agents Chemother; Pediatr Infect Dis J; Pediatrics; BMJ; JAMA; Lancet; J Clin Epidemiol; J Antimicrob Chemother; Pediatrics; JAMA; Pediatr Infect Dis J; Pediatr Infect Dis J",NA,NA,"1174-5878","71-80",NA,"Pediatric Drugs",NA,"2003","2","5","Current Treatment Strategies",NA,NA
"Respiration","2006-11-03","2024-09-12","2005-07-21","10.1159/000096833","2024-09-13","2005-07-21","127","10.1159","S. Karger AG","18.85837","Crossref","19","19","0","Genetic Predisposition to Asthma and Atopy","journal-article","http://dx.doi.org/10.1159/000096833","en","Despina G.; Ioanna N.; John P.A.; Contopoulos-Ioannidis; Kouri; Ioannidis; first; additional; additional","https://www.karger.com/Article/Pdf/96833; https://www.karger.com/Article/Pdf/96833; application/pdf; unspecified; vor; vor; text-mining; similarity-checking","ref1; ref2; ref3; ref4; ref5; ref6; ref7; ref8; ref9; ref10; ref11; ref12; ref13; ref14; ref15; ref16; ref17; ref18; ref19; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; 10.1007%2Fs10038-006-0007-3; 10.1136%2Fthx.2005.051284; 10.1016%2FS0140-6736%2806%2969287-8; 10.1016%2Fj.jaci.2004.12.1119; 10.1159%2F000078648; 10.1093%2Faje%2Fkwi184; 10.1136%2Fthx.2004.027227; 10.1038%2Fsj.ejhg.5201662; 10.1136%2Fthx.2004.028449; 10.1016%2Fj.jaci.2004.02.008; 10.1038%2Fnature00878; 10.1016%2Fj.jaci.2006.03.037; 10.1097%2F01.fpc.0000236332.11304.8f; 10.1016%2FS1471-4914%2803%2900030-3; 10.1093%2Faje%2Fkwj259; 10.1038%2Fng749; 10.1038%2Fnrg1578; 10.1093%2Fjnci%2Fdjh075; 10.1016%2Fj.tig.2006.05.001","<jats:p>A large number of studies have tried to identify heritable components in the susceptibility to asthma and atopy phenotypes. This review examines the evidence of multigenetic inheritance for these conditions. We identified in the literature at least 372 gene-disease association studies for asthma and 124 for atopy published in the last 6 years. Gene-environment analyses were performed in 41 and 14 articles, respectively, in the same time period. Many postulated associations have been probed with limited sample sizes and will require more extensive replication and large-scale evidence. Meta-analyses have been performed for polymorphisms in 5 genes and provide modest evidence for genetic association of asthma with &lt;i&gt;ADAM33 &lt;/i&gt;and &lt;i&gt;TNFA&lt;/i&gt; gene polymorphisms. Meta-analyses of linkage studies show that it is unlikely to detect strong linkage peaks for asthma susceptibility. However, linkage was claimed between loci on chromosomes 2, 4, 6, 9, 10, 11 and 15 and total serum IgE levels. Careful definitions and standardization of phenotypes across teams of investigators are important to endorse. New large-scale testing platforms may offer new opportunities for discovering susceptibility gene variants, but they need to be coupled with careful study design, international collaboration, and possibly also dissection of gene-environment interactions.</jats:p>",NA,"0025-7931,1423-0356","8-12",NA,"Respiration","2005-07-21; 2005-07-21; vor; tdm; 0; 0; https://www.karger.com/Services/SiteLicenses; https://www.karger.com/Services/SiteLicenses","2007","1","74",NA,"Portico",NA
"Pediatric Drugs","2006-01-23","2023-05-06",NA,"10.2165/00128072-200305020-00001","2023-05-06","2003","297","10.1007","Springer Science and Business Media LLC","18.76675","Crossref","49","49","9","Acute Sinusitis in Children","journal-article","http://dx.doi.org/10.2165/00128072-200305020-00001","en","Despina G.; John P.A.; Joseph; Contopoulos-Ioannidis; Ioannidis; Lau; first; additional; additional",NA,"R1-1; R2-1; R3-1; R4-1; R5-1; R6-1; R7-1; R8-1; R9-1; R10-1; R11-1; R12-1; R13-1; R14-1; R15-1; R16-1; R17-1; R18-1; R19-1; R20-1; R21-1; R22-1; R23-1; R24-1; R25-1; R26-1; R27-1; R28-1; R29-1; R30-1; R31-1; R32-1; R33-1; R34-1; R35-1; R37-1; R38-1; R39-1; R40-1; R41-1; R42-1; R43-1; R44-1; R45-1; R46-1; R47-1; R48-1; R50-1; R51-1; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; NA; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; 1209; 319; E57; 38; 543; 297; 795; 375; 64; 413; 83; 43; 547; 50; 21; 342; 244; 576; 301; 457; 598; 619; 269; 256; 93; 165; 288; 225; 23; 121; 41; 49; 139; 45; 749; 701; 798; 292; 1; 166; 632; 437; 1752; 619; 677; 239; 49; 829; 963; 10.1093/clinids/23.6.1209; 10.1056/NEJM199201303260507; 10.1542/peds.108.3.e57; 10.1179/joc.1997.9.1.38; 10.1080/1120009X.1993.11741114; 10.1016/S0022-3476(84)81018-5; 10.1542/peds.77.6.795; 10.3109/00016487209128466; NA; 10.1177/030006058000800609; NA; 10.3109/inf.1972.4.issue-1.09; 10.1093/jac/38.3.547; 10.1159/000221971; 10.2165/00003495-198600323-00005; 10.1177/000992287000900611; NA; 10.1097/00006454-199607000-00003; 10.1016/0165-5876(82)90042-8; 10.1177/000992289603500905; 10.1016/S1081-1206(10)63223-1; 10.1542/peds.107.4.619; 10.1177/000992289903800503; 10.1007/s004050050234; NA; 10.1542/peds.109.1.165; 10.1007/BF02597398; 10.1023/A:1008883508462; 10.1016/S0165-5876(99)00201-3; 10.1542/peds.52.1.121; 10.1111/j.1365-2273.1977.tb01333.x; 10.1111/j.1365-2273.1992.tb00987.x; 10.1016/0165-5876(82)90089-1; 10.1016/S0022-3476(89)80599-2; 10.1056/NEJM198103263041302; 10.1111/j.1525-1497.2001.00429.x; 10.1542/peds.108.3.798; 10.1128/AAC.41.2.292; 10.1097/00006454-199901000-00002; 10.1542/peds.109.1.166; 10.1136/bmj.317.7159.632; 10.1001/jama.285.4.437; 10.1016/S0140-6736(05)79825-1; 10.1016/S0895-4356(02)00393-1; 10.1093/jac/48.5.677; 10.1542/peds.108.2.239; 10.1001/jama.286.1.49; 10.1097/00006454-200109000-00002; 10.1097/00006454-199810000-00041; 23; 326; 108; 9; 5; 104; 77; 74; 14; 8; 37; 4; 38; 23; 32; 9; 152; 15; 4; 35; 78; 107; 38; 257; 15; 109; 4; 8; 50; 52; 2; 17; 4; 114; 304; 16; 108; 41; 18; 109; 317; 285; 352; 55; 48; 108; 286; 20; 17; Gwaltney; Wald; Ioannidis; Ficnar; Careddu; Wald; Wald; Jeppesen; Simon; Hager; Helin; Nylen; Gurses; Herz; Puhakka; McLean; Aitken; Ueda; Revonta; McCormick; Barlan; Garbutt; Simon; Yilmaz; Simon; Karadag; Mulrow; Garbutt; Sacco; Kogutt; Watt-Boolsen; Van Buchem; Jannert; Glasier; Wald; Balk; NA; Doern; Dowell; Harris; de Ferranti; Ioannidis; Ioannidis; Ioannidis; Ioannidis; Takata; Schrag; Dagan; Bottenfield; 1996; 1992; 2002; 1997; 1993; 1984; 1986; 1972; 1997; 1980; 1982; 1972; 1996; 1977; 1986; 1970; 1998; 1996; 1982; 1996; 1997; 2001; 1999; 2000; 2000; 2002; 1989; 1999; 1999; 1973; 1977; 1992; 1982; 1989; 1981; 2001; 2001; 1997; 1999; 2002; 1998; 2001; 1998; 2002; 2001; 2001; 2001; 2001; 1998; Clin Infect Dis; N Engl J Med; Pediatrics; J Chemother; J Chemother; J Pediatr; Pediatrics; Acta Otolaryngol; Adv Ther; J Int Med Res; Helv Paediatr Acta; Scand J Infect Dis; J Antimicrob Chemother; Chemotherapy; Drugs; Clin Pediatr (Phila); Arch Pediatr Adolesc Med; Pediatr Infect Dis J; Int J Pediatr Otorhinolaryngol; Clin Pediatr (Phila); Allergy Asthma Immunol; Pediatrics; Clin Pediatr; Eur Arch Otorhinolaryngol; Int Pediatr; Pediatrics; J Gen Intern Med; Qual Life Res; Int J Pediatr Otorhinolaryngol; Pediatrics; Clin Otolaryngol; Clin Otolaryngol; Int J Pediatr Otorhinolaryngol; J Pediatr; N Engl J Med; J Gen Intern Med; Pediatrics; Antimicrob Agents Chemother; Pediatr Infect Dis J; Pediatrics; BMJ; JAMA; Lancet; J Clin Epidemiol; J Antimicrob Chemother; Pediatrics; JAMA; Pediatr Infect Dis J; Pediatr Infect Dis J",NA,NA,"1174-5878","71-80",NA,"Pediatric Drugs",NA,"2003","2","5","Current Treatment Strategies",NA,NA
NA,"2018-07-02","2022-08-30",NA,"10.31222/osf.io/fzpcy","2024-03-04","2018-04-16","15934","10.31228","Center for Open Science","18.628584","Crossref","0","0","5","Mapping the Universe of Registered Reports","posted-content","http://dx.doi.org/10.31222/osf.io/fzpcy",NA,"http://orcid.org/0000-0001-9485-4952; NA; TRUE; NA; Tom Elis; john; Hardwicke; Ioannidis; first; additional",NA,NA,"<p>Registered reports present a substantial departure from traditional publishing models with the goal of enhancing the transparency and credibility of the scientific literature. We map the evolving universe of registered reports to assess their growth, implementation, and shortcomings at journals across scientific disciplines.</p>",NA,NA,NA,NA,NA,"2018-04-16; unspecified; 0; https://creativecommons.org/publicdomain/zero/1.0/legalcode",NA,NA,NA,NA,NA,NA
"Pediatrics","2005-03-01","2021-12-11","2005-03-01","10.1542/peds.2004-2721","2023-09-13","2005-03-01","417","10.1542","American Academy of Pediatrics (AAP)","18.551373","Crossref","6","6","0","Extended-Interval Aminoglycosides in Children: More Guidance Is Needed: In Reply","journal-article","http://dx.doi.org/10.1542/peds.2004-2721","en","Despina G.; John P.A.; Contopoulos-Ioannidis; Ioannidis; first; additional; Department of Pediatrics and Hygiene and Epidemiology,&#x2028; University of Ioannina School of Medicine, &#x2028; 45110 Ioannina, Greece; Department of Pediatrics and Hygiene and Epidemiology,&#x2028; University of Ioannina School of Medicine, &#x2028; 45110 Ioannina, Greece","https://publications.aap.org/pediatrics/article-pdf/115/3/828/1019731/zpe00305000828.pdf; https://publications.aap.org/pediatrics/article-pdf/115/3/828/1019731/zpe00305000828.pdf; application/pdf; unspecified; vor; vor; syndication; similarity-checking","2021121021580236800_R1A; 2021121021580236800_R2A; 2021121021580236800_R3A; 2021121021580236800_R4A; 2021121021580236800_R5A; 2021121021580236800_R6A; crossref; crossref; crossref; crossref; crossref; crossref; Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443; Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788; Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338–345; Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78–84; Winston L, Benowitz N. Once-daily dosing of aminoglycosides: how much monitoring is truly required?Am J Med. 2003;114:239–240; Nicolaou DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–655; 10.1001/jama.285.4.437; 10.7326/0003-4819-141-10-200411160-00009; 10.1136/bmj.312.7027.338; 10.7326/0003-4819-116-1-78; 10.1016/S0002-9343(03)00012-3; 10.1128/AAC.39.3.650",NA,NA,"0031-4005,1098-4275","828-828",NA,NA,NA,"2005-03-01","3","115",NA,NA,NA
"Encyclopedia of Cryptography and Security","2011-10-27","2020-06-01",NA,"10.1007/978-1-4419-5906-5_269","2024-09-06","2011","297","10.1007","Springer US","18.451033","Crossref","1","1","3","IPsec","book-chapter","http://dx.doi.org/10.1007/978-1-4419-5906-5_269","en","John; Ioannidis; first","http://link.springer.com/content/pdf/10.1007/978-1-4419-5906-5_269; unspecified; vor; similarity-checking","269_CR1_269; IPsec is still evolving. As of this writing, the core set of standards documents are RFCs 4301-4309. Many other RFCs address individual aspects. The interested reader is referred to the IETF web page (
                  http://www.ietf.org
                  
                 for the authoritative RFC repository.",NA,NA,NA,"635-638",NA,NA,"2011-01-01; 2011-01-01; tdm; vor; 0; 0; http://www.springer.com/tdm; http://www.springer.com/tdm","2011",NA,NA,NA,NA,"9781441959058,9781441959065"
NA,"2022-10-11","2023-05-18",NA,"10.1101/2022.10.07.22280814","2023-05-19","2022-10-10","246","10.1101","Cold Spring Harbor Laboratory","18.422377","Crossref","30","30","0","Pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis","posted-content","http://dx.doi.org/10.1101/2022.10.07.22280814",NA,"http://orcid.org/0000-0003-3118-6859; NA; FALSE; NA; John P.A.; Despina G.; Ioannidis; Contopoulos-Ioannidis; first; additional","https://syndication.highwire.org/content/doi/10.1101/2022.10.07.22280814; unspecified; vor; similarity-checking","2023051813201012000_2022.10.07.22280814v3.1; 2023051813201012000_2022.10.07.22280814v3.2; 2023051813201012000_2022.10.07.22280814v3.3; 2023051813201012000_2022.10.07.22280814v3.4; 2023051813201012000_2022.10.07.22280814v3.5; 2023051813201012000_2022.10.07.22280814v3.6; 2023051813201012000_2022.10.07.22280814v3.7; 2023051813201012000_2022.10.07.22280814v3.8; 2023051813201012000_2022.10.07.22280814v3.9; 2023051813201012000_2022.10.07.22280814v3.10; 2023051813201012000_2022.10.07.22280814v3.11; 2023051813201012000_2022.10.07.22280814v3.12; 2023051813201012000_2022.10.07.22280814v3.13; 2023051813201012000_2022.10.07.22280814v3.14; 2023051813201012000_2022.10.07.22280814v3.15; 2023051813201012000_2022.10.07.22280814v3.16; 2023051813201012000_2022.10.07.22280814v3.17; 2023051813201012000_2022.10.07.22280814v3.18; 2023051813201012000_2022.10.07.22280814v3.19; 2023051813201012000_2022.10.07.22280814v3.20; 2023051813201012000_2022.10.07.22280814v3.21; 2023051813201012000_2022.10.07.22280814v3.22; 2023051813201012000_2022.10.07.22280814v3.23; 2023051813201012000_2022.10.07.22280814v3.24; 2023051813201012000_2022.10.07.22280814v3.25; 2023051813201012000_2022.10.07.22280814v3.26; 2023051813201012000_2022.10.07.22280814v3.27; 2023051813201012000_2022.10.07.22280814v3.28; 2023051813201012000_2022.10.07.22280814v3.29; 2023051813201012000_2022.10.07.22280814v3.30; publisher; publisher; crossref; publisher; publisher; NA; NA; NA; NA; crossref; crossref; crossref; crossref; crossref; publisher; publisher; publisher; crossref; NA; crossref; crossref; publisher; publisher; publisher; publisher; crossref; crossref; NA; crossref; crossref; 10.9745/GHSP-D-21-00172; 10.1007/s10654-021-00787-9; 10.15171/ijhpm.2014.71; 10.7326/0003-4819-127-9-199711010-00008; 10.1111/j.1365-2753.2008.00986.x; NA; NA; NA; NA; 10.1038/s41598-022-26709-7; 10.3201/eid2802.211725; 10.3389/fimmu.2022.941923; 10.3390/tropicalmed7070132; 10.15585/mmwr.mm7110a3; 10.1186/s12985-021-01522-2; 10.1016/j.ijid.2020.09.1451; 10.1590/0074-02760200225; 10.1093/cid/ciaa1207; NA; 10.3390/v14102259; 10.3201/eid2811.221041; 10.1016/j.ijid.2022.11.041; 10.1038/s41586-020-2550-z; 10.1056/NEJMoa2118946; 10.1101/2023.01.16.23284626; 10.1126/science.abd3871; 10.1038/s41586-020-2598-9; NA; 10.7554/eLife.82050; 10.1016/j.diagmicrobio.2023.115903; NA; NA; 3; NA; NA; NA; NA; NA; 1; 1; NA; NA; 7; 10; NA; NA; NA; 7; NA; 10; 11; NA; NA; NA; NA; NA; 7833; NA; NA; 4; NA; NA; 123; NA; NA; NA; NA; NA; 6; 22175; 440; 941923; 132; 375; NA; NA; NA; e2444; NA; 2259; 2214; NA; NA; NA; NA; NA; 270; NA; e82050; 115903; NA; NA; The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence; NA; NA; NA; NA; NA; Redefine statistical significance; Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 spike protein; SARS-CoV-2 cross-reactivity in prepandemic serum from rural malaria-infected persons, Cambodia; Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis; False positivity of anti-SARS-CoV-2 antibodies in patients with acute tropical diseases in Thailand; Evaluation of serologic cross-reactivity between dengue virus and SARS-CoV-2 in patients with acute febrile illness - United States and Puerto Rico, April 2020-March 2021; NA; NA; NA; Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses; NA; Pre-Pandemic cross-reactive immunity against SARS-CoV-2 among Central and West African populations; Coronavirus antibody responses before COVID-19 pandemic, Africa and Thailand; NA; NA; NA; NA; NA; SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19; NA; SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells; Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings; NA; NA; 3; NA; NA; NA; NA; NA; 2; 12; 28; 13; 7; 71; NA; NA; NA; 73; NA; 14; 28; NA; NA; NA; NA; NA; 587; NA; 11; 105; NA; NA; 2014; NA; NA; NA; NA; NA; 2018; 2022; 2022; 2022; 2022; 2022; NA; NA; NA; 2021; NA; 2022; 2022; NA; NA; NA; NA; NA; 2020; NA; 2022; 2023; NA; NA; Int J Heal Policy Manag; NA; NA; NA; NA; NA; Nat Hum Behav; Sci Rep; Emerg Infect Dis; Front Immunol; Trop Med Infect Dis; MMWR Morb Mortal Wkly Rep; NA; NA; NA; Clin Infect Dis; NA; Viruses; Emerg Infect Dis; NA; NA; NA; NA; NA; Nature; NA; Elife; Diagn Microbiol Infect Dis; NA; NA; NA; NA; NA; CDC. Malaria distribution, in: https://www.cdc.gov/malaria/about/distribution.html, last accessed September 13, 2022.; Dengue Global Consensus 2013 map, in https://www.healthmap.org/dengue/en/, last accessed September 13, 2022.; AIDS adult prevalence, in https://en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate, last accessed September 13, 2022.; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; WHO. Dengue and severe dengue, update Jan 10, 2022.; NA; NA; NA; NA; NA; NA; Mateus J , Grifoni A , Tarke A , Sidney J , Ramirez SI , Dan JM , et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in 284 unexposed humans. Science 2020;370(6512).; NA; NA; NA; NA","<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To assess the evidence on the presence of antibodies cross-reactive with SARS-CoV-2 antigens in pre-pandemic samples from African populations.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a systematic review and meta-analysis of studies evaluating pre-pandemic African samples using pre-set assay-specific thresholds for SARS-CoV-2 seropositivity.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>26 articles with 156 datasets were eligible, including 3,437 positives among 29,923 measurements (11.5%) with large between-dataset heterogeneity. Positivity was similar for anti-N (14%) and anti-S antibodies (11%), higher for anti-S1 (23%) and lower for anti-RBD antibodies (7%). Positivity was similar, on average, for IgM and IgG. Positivity was seen prominently in countries where malaria transmission occurs throughout and in datasets enriched in malaria cases (14%, 95% CI, 12-15% versus 2%, 95% CI 1-2% in other datasets). Substantial SARS-CoV-2 reactivity was seen in high malaria burden with or without high dengue burden (14% and 12%, respectively), and not without high malaria burden (2% and 0%, respectively). Lower SARS-CoV-2 cross-reactivity was seen in countries and cohorts of high HIV seroprevalence. More sparse individual-level data showed associations of higher SARS-CoV-2 cross-reactivity with<jats:italic>Plasmodium</jats:italic>parasitemia and lower SARS-CoV-2 cross-reactivity with HIV seropositivity.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Pre-pandemic samples from Africa show high levels of anti-SARS-CoV-2 seropositivity. Levels of cross-reactivity tracks especially with malaria prevalence.</jats:p></jats:sec>",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Journal of Clinical Epidemiology","2002-07-25","2023-04-12",NA,"10.1016/s0895-4356(98)00159-0","2024-09-13","1999-04","78","10.1016","Elsevier BV","18.396461","Crossref","49","49","65","Recursive Cumulative Meta-analysis","journal-article","http://dx.doi.org/10.1016/s0895-4356(98)00159-0","en","John P.A; Despina G; Joseph; Ioannidis; Contopoulos-Ioannidis; Lau; first; additional; additional","https://api.elsevier.com/content/article/PII:S0895435698001590?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0895435698001590?httpAccept=text/plain; text/xml; text/plain; vor; vor; text-mining; text-mining","10.1016/S0895-4356(98)00159-0_BIB1; 10.1016/S0895-4356(98)00159-0_BIB2; 10.1016/S0895-4356(98)00159-0_BIB3; 10.1016/S0895-4356(98)00159-0_BIB4; 10.1016/S0895-4356(98)00159-0_BIB5; 10.1016/S0895-4356(98)00159-0_BIB6; 10.1016/S0895-4356(98)00159-0_BIB7; 10.1016/S0895-4356(98)00159-0_BIB8; 10.1016/S0895-4356(98)00159-0_BIB9; 10.1016/S0895-4356(98)00159-0_BIB10; 10.1016/S0895-4356(98)00159-0_BIB11; 10.1016/S0895-4356(98)00159-0_BIB12; 10.1016/S0895-4356(98)00159-0_BIB13; 10.1016/S0895-4356(98)00159-0_BIB14; 10.1016/S0895-4356(98)00159-0_BIB15; 10.1016/S0895-4356(98)00159-0_BIB16; 10.1016/S0895-4356(98)00159-0_BIB17; 10.1016/S0895-4356(98)00159-0_BIB18; 10.1016/S0895-4356(98)00159-0_BIB19; 10.1016/S0895-4356(98)00159-0_BIB20; 10.1016/S0895-4356(98)00159-0_BIB21; 10.1016/S0895-4356(98)00159-0_BIB22; 10.1016/S0895-4356(98)00159-0_BIB23; 10.1016/S0895-4356(98)00159-0_BIB24; 10.1016/S0895-4356(98)00159-0_BIB25; 10.1016/S0895-4356(98)00159-0_BIB26; 10.1016/S0895-4356(98)00159-0_BIB27; 10.1016/S0895-4356(98)00159-0_BIB28; 10.1016/S0895-4356(98)00159-0_BIB29; 10.1016/S0895-4356(98)00159-0_BIB30; 10.1016/S0895-4356(98)00159-0_BIB31; 10.1016/S0895-4356(98)00159-0_BIB32; 10.1016/S0895-4356(98)00159-0_BIB33; 10.1016/S0895-4356(98)00159-0_BIB34; 10.1016/S0895-4356(98)00159-0_BIB35; 10.1016/S0895-4356(98)00159-0_BIB36; 10.1016/S0895-4356(98)00159-0_BIB37; 10.1016/S0895-4356(98)00159-0_BIB38; 10.1016/S0895-4356(98)00159-0_BIB39; 10.1016/S0895-4356(98)00159-0_BIB40; 10.1016/S0895-4356(98)00159-0_BIB41; 10.1016/S0895-4356(98)00159-0_BIB42; 10.1016/S0895-4356(98)00159-0_BIB43; 10.1016/S0895-4356(98)00159-0_BIB44; 10.1016/S0895-4356(98)00159-0_BIB45; 10.1016/S0895-4356(98)00159-0_BIB46; 10.1016/S0895-4356(98)00159-0_BIB47; 10.1016/S0895-4356(98)00159-0_BIB48; 10.1016/S0895-4356(98)00159-0_BIB49; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; NA; crossref; crossref; crossref; crossref; crossref; NA; crossref; NA; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; 1385; 281; 2057; 418; 917; 183S; 248; 45; 357; 719; 177; NA; 820; 349; 933; 197; 641; 669; 1015; NA; NA; NA; 221; 683; 1125; 127; 1337; 25; 1923; 669; 873; 41; 1231; 209S; 123; 580; 1935; 772; 1332; 536; 1089; 1181; 1517; 856; 22; 1713; 1074; 1089; 93; 10.1001/jama.1990.03440100097014; 10.1001/jama.279.4.281; 10.1002/sim.4780141902; 10.1016/0140-6736(93)93004-K; 10.1093/oxfordjournals.aje.a009051; 10.1016/S0197-2456(97)91213-7; 10.1056/NEJM199207233270406; 10.1016/0895-4356(94)00106-Z; 10.1016/S0197-2456(96)00014-1; NA; 10.1016/0197-2456(86)90046-2; NA; 10.7326/0003-4819-127-9-199711010-00008; 10.1086/515621; 10.1097/00002030-199108000-00003; 10.1097/00002030-199302000-00007; 10.1097/00002030-199405000-00010; NA; 10.1056/NEJM199010113231502; NA; 10.1097/00002030-199411004-00056; NA; 10.1136/bmj.316.7126.221; 10.1136/bmj.306.6879.683; 10.1136/bmj.306.6885.1125-b; 10.1016/0166-3542(90)90028-6; 10.1097/00002030-199310000-00006; 10.1177/135965359800300101; 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; 10.1016/S0140-6736(95)90865-X; 10.7326/0003-4819-123-11-199512010-00010; 10.2307/2532737; 10.1002/sim.4780071204; 10.1016/0197-2456(89)90059-7; 10.1016/S0140-6736(97)08468-7; 10.1016/S0197-2456(97)00051-2; 10.1001/jama.1995.03530240045039; 10.1016/S0140-6736(95)90646-0; 10.1001/jama.1996.03540160054033; 10.1056/NEJM199708213370806; 10.1001/jama.279.14.1089; 10.1016/S0140-6736(05)63832-9; 10.1016/S0140-6736(05)78914-5; 10.7326/0003-4819-122-11-199506010-00009; 10.1097/00042560-199709010-00004; 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; 10.1093/oxfordjournals.aje.a008881; 10.1016/S0895-4356(97)00149-2; 10.1001/jama.1991.03470010097038; The existence of publication bias and risk factors for its occurrence; Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials; Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group; Meta-analysis of the literature or of individual patient data; Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies; Prospective meta-analysis using individual patient data vs. meta-analysis of published reports; Cumulative meta-analysis of trials of treatments for myocardial infarction; Cumulative meta-analysis builds evidence for exemplary medical care; Uncertainty of the time of first significance in random effects cumulative meta-analysis; Statistical aspects of the analysis of data from retrospective studies of disease; Meta-analysis in clinical trials; NA; Quantitative synthesis in systematic reviews; Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection; The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex; The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex; Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease; A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients; A pilot study of low-dose zidovudine in human immunodeficiency virus infection; NA; NA; NA; Meta-analysis. Unresolved issues and future developments; Selective serotonin inhibitors; Effective and acceptable treatment for depression; Long-term zidovudine treatment of asymptomatic HIV-1 infected subjects; Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment; Lack of effect on survival of high-dose acyclovir and zidovudine compared with zidovudine alone for acquired immunodeficiency syndrome; An empirical study of the effect of the control rate as a predictor of treatment efficacy in a meta-analysis of clinical trials; ISIS-4; Discordance between meta-analyses and large-scale randomized, controlled trials; The impact of stopping rules on heterogeneity of results in overviews of clinical trials; Stopping rules and estimation problems in clinical trials; Practical problems in interim analyses, with particular regard to estimation; Summing up evidence; Cumulative evidence from randomized trials; The Cochrane Collaboration; Predictive ability of meta-analysis of randomized controlled trials; Large trials versus meta-analyses of small trials; Discrepancies between meta-analyses and subsequent large randomized, controlled trials; Issues in comparisons between meta-analyses and large trials; Meta-analyses of randomised controlled trials; Meta-analysis; Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness; Predictors and impact of patients lost to follow-up in a long-term trial of early versus deferred antiretroviral treatment; The population risk as an explanatory variable in research synthesis of clinical trials; Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates; The impact of high risk patients on the results of clinical trials; Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials; 263; 279; 14; 341; 145; 18; 327; 48; 17; 22; 7; NA; 126; 178; 5; 7; 8; 14; 323; NA; NA; NA; 316; 306; 306; 13; 7; 3; 17; 345; 123; 48; 7; 10; 351; 18; 274; 345; 276; 337; 279; 350; 351; 122; 16; 15; 144; 50; 266; Dickersin; Ioannidis; Stewart; Stewart; Steinberg; Franzosi; Lau; Lau; Berkey; Mantel; Der Simonian; Cox; Lau; Ioannidis; Cooper; Cooper; Youle; Chavanet; Collier; NA; NA; NA; Smith; Song; Nakielny; Mulder; Luxton; Collier; Schmid; ISIS-4 Collaborative Group; Borzak; Hughes; Hughes; Pocock; Lau; Pogue; Bero; Villar; Cappelleri; LeLorier; Ioannidis; Rothwell; Egger; Ioannidis; Ioannidis; McIntosh; Ioannidis; Ioannidis; Yusuf; 1990; 1998; 1995; 1993; 1997; 1997; 1992; 1995; 1996; 1959; 1986; 1984; 1997; 1998; 1991; 1993; 1994; 1990; 1990; NA; NA; NA; 1998; 1993; 1993; 1990; 1993; 1998; 1998; 1995; 1995; 1992; 1988; 1989; 1998; 1997; 1995; 1995; 1996; 1997; 1998; 1998; 1998; 1995; 1997; 1996; 1996; 1997; 1991; JAMA; JAMA; Stat Med; Lancet; Am J Epidemiol; Control Clin Trials; N Engl J Med; J Clin Epidemiol; Control Clin Trials; J Natl Cancer Inst; Control Clin Trials; NA; Ann Intern Med; J Infect Dis; AIDS; AIDS; AIDS; Cancer Detect Prev; N Engl J Med; NA; NA; NA; BMJ; BMJ; BMJ; Antiviral Res; AIDS; Antiviral Ther; Stat Med; Lancet; Ann Intern Med; Biometrics; Stat Med; Control Clin Trials; Lancet; Control Clin Trials; JAMA; Lancet; JAMA; N Engl J Med; JAMA; Lancet; Lancet; Ann Intern Med; J Acquir Immune Defic Syndr Hum Retrovirol; Stat Med; Am J Epidemiol; J Clin Epidemiol; JAMA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Analysis of Survival Data; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Lavelle J, Lang W, Lefkowitz L, et al. A randomized trial comparing zidovudine alone and in combination with acyclovir for treatment of early symptomatic HIV infection. In: Abstracts of the VIII International Conference on AIDS, Amsterdam, 1992. (Abstract PoB 3585); Cooper DA, Gazzard GB, Stevens J, Bell AR. The effect of acyclovir cotherapy on survival in individuals with advanced HIV disease. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994 Oct 4–7. (Abstract 61); Collier AC, Schoenfeld DA, Bourland D, Hirsch M, Davis LG, Corey L. Prospective comparative study of acyclovir and zidovudine versus zidovudine alone in patients with AIDS. In: Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections, January 29–February 2, 1995. (Abstract 383); NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Suppl. 4; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA",NA,"S0895435698001590","0895-4356","281-291",NA,"Journal of Clinical Epidemiology","1999-04-01; tdm; 0; https://www.elsevier.com/tdm/userlicense/1.0/","1999-04","4","52",NA,NA,NA
"Pediatrics","2021-08-31","2022-01-04","2021-09-01","10.1542/peds.2020-049771","2023-06-14","2021-09-01","417","10.1542","American Academy of Pediatrics (AAP)","18.329409","Crossref","30","30","5","Large Pediatric Randomized Clinical Trials in ClinicalTrials.gov","journal-article","http://dx.doi.org/10.1542/peds.2020-049771","en","Stephanie M.; Stylianos; John PA.; Terry P.; Despina G.; Cho; Serghiou; Ioannidis; Klassen; Contopoulos-Ioannidis; first; additional; additional; additional; additional; Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California94305; NA; NA; Department of Pediatrics and Child Health, University of Manitoba and Children’s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada; Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California; NA; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California; 94305; Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California94305; NA; NA; NA; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California; 94305; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California; 94305; NA; NA; NA; NA; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California; 94305; NA; NA","https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2020-049771/1227650/peds_2020049771.pdf; https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2020-049771/1227650/peds_2020049771.pdf; application/pdf; unspecified; vor; vor; syndication; similarity-checking","8; 6; 3; 2; 1; NA; NA; NA; NA; NA; NA; NA; NA; NA; 3; 3; 1; NA; 3; NA; 3; NA; NA; 2; 8; 10064; 10100; 2; NA; NA; 2022010420533293200_B1; 2022010420533293200_B2; 2022010420533293200_B3; 2022010420533293200_B4; 2022010420533293200_B5; 2022010420533293200_B6; 2022010420533293200_B7; 2022010420533293200_B8; 2022010420533293200_B9; 2022010420533293200_B10; 2022010420533293200_B11; 2022010420533293200_B12; 2022010420533293200_B13; 2022010420533293200_B14; 2022010420533293200_B15; 2022010420533293200_B16; 2022010420533293200_B17; 2022010420533293200_B18; 2022010420533293200_B19; 2022010420533293200_B20; 2022010420533293200_B21; 2022010420533293200_B22; 2022010420533293200_B23; 2022010420533293200_B24; 2022010420533293200_B25; 2022010420533293200_B26; 2022010420533293200_B27; 2022010420533293200_B28; 2022010420533293200_B29; 2022010420533293200_B30; crossref; crossref; crossref; crossref; crossref; crossref; NA; NA; NA; NA; NA; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; crossref; crossref; crossref; NA; crossref; crossref; crossref; crossref; crossref; NA; NA; e172; e20182997; 267; e25; 78; k1452; NA; NA; NA; NA; NA; 53; 28; NA; 244; e255; 37; 277; 127; g3058; e20160223; j3064; NA; 241; e1002632; 16; 1260; 197; NA; NA; 10.1371/journal.pmed.0050172; 10.1542/peds.2018-2997; 10.1001/jamapediatrics.2015.4276; 10.1542/pir.32.2.e25; 10.1542/peds.2013-2567; 10.1136/bmj.k1452; NA; NA; NA; NA; NA; 10.2147/DDDT.S30109; 10.1186/s12961-015-0019-6; NA; 10.1093/phe/phx012; 10.1016/S2214-109X(18)30045-7; 10.1186/s12939-018-0748-6; 10.3389/fped.2017.00277; 10.1136/bmjebm-2018-111154; 10.1136/bmj.g3058; 10.1542/peds.2016-0223; 10.1136/bmj.j3064; NA; 10.3945/ajcn.114.105072; 10.1371/journal.pmed.1002632; 10.1016/S0140-6736(16)32185-7; 10.1016/S0140-6736(17)32130-X; 10.1177/003335490912400206; NA; NA; Children are not just small adults: the urgent need for high-quality trial evidence in children; The role of pediatricians in global health; Global and national burden of diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study; Global child health; Association between pediatric clinical trials and global burden of disease; How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider; NA; NA; NA; NA; NA; Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world; Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013; NA; Out of alignment? Limitations of the global burden of disease in assessing the allocation of global health aid; Global disability-adjusted life-year estimates of long-term health burden and undernutrition attributable to diarrhoeal diseases in children younger than 5 years; Barriers for conducting clinical trials in developing countries- a systematic review; Challenges and priorities for pediatric critical care clinician-researchers in low- and middle-income countries; Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research; Non-publication and delayed publication of randomized trials on vaccines: survey; Discontinuation and nonpublication of randomized clinical trials conducted in children; How to design efficient cluster randomised trials; NA; Best (but oft-forgotten) practices: designing, analyzing, and reporting cluster randomized controlled trials; Choices in vaccine trial design in epidemics of emerging infections; The invisible child: childhood heart disease in global health; Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [published correction appears in Lancet. 2017;390(10106):e38]; Disability and disability-adjusted life years: not the same; NA; NA; 5; 142; 170; 32; 133; 361; NA; NA; NA; NA; NA; 6; 13; NA; 10; 6; 17; 5; 26; 348; 138; 358; NA; 102; 15; 389; 390; 124; NA; NA; Klassen; Suchdev; Kyu; Denno; Bourgeois; Tse; NA; R Core Team; NA; NA; NA; Caldron; Murthy; NA; Voigt; Troeger; Alemayehu; von Saint André-von Arnim; Jakobsen; Manzoli; Pica; Hemming; NA; Brown; Kahn; Zheleva; GBD 2016 DALYs and HALE Collaborators; Grosse; NA; NA; 2008; 2018; 2016; 2011; 2014; 2018; NA; 2018; NA; NA; NA; 2012; 2015; NA; 2017; 2018; 2018; 2017; 2019; 2014; 2016; 2017; NA; 2015; 2018; 2017; 2017; 2009; NA; NA; PLoS Med; Pediatrics; JAMA Pediatr; Pediatr Rev; Pediatrics; BMJ; NA; NA; NA; NA; NA; Drug Des Devel Ther; Health Res Policy Syst; NA; Public Health Ethics; Lancet Glob Health; Int J Equity Health; Front Pediatr; BMJ Evid Based Med; BMJ; Pediatrics; BMJ; NA; Am J Clin Nutr; PLoS Med; Lancet; Lancet; Public Health Rep; NA; NA; NA; NA; NA; NA; NA; NA; US National Library of Medicine
          . Advanced search. 2020. Available at: https://clinicaltrials.gov/ct2/search/advanced?cond=&term=&cntry= &state=&city=&dist=. Accessed January 1, 2020; NA; Internal Revenue Service
          . Exemption requirements – 501(c)(3) organizations. Available at: https://www.irs.gov/charities-non-profits/charitable-organizations/exemption-requirements-501c3-organizations. Accessed December 7, 2020; Investopedia
          . Not for profit. Available at: https://www.investopedia.com/terms/n/not-for-profit.asp. Accessed December 7, 2020; The World Bank
          . World Bank country and lending groups. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed June 15, 2020; NA; NA; Institute for Health Metrics and Evaluation
          . GBD compare. 2020. Available at: https://vizhub.healthdata.org/gbd-compare/. Accessed June 12, 2020; NA; NA; NA; NA; NA; NA; NA; NA; World Health Organization
          . International clinical trials registry platform. 2021. Available at: https://www.who.int/clinical-trials-registry-platform. Accessed March 1, 2021; NA; NA; NA; NA; NA; World Health Organization
          . International classification of functioning, disability and health (ICF). 2001. Available at: https://www.who.int/standards/classifications/ international-classification-of-functioning-disability-and-health. Accessed July 20, 2020; World Health Organization
          . Noncommunicable diseases. 2015. Available at: www.who.int/topics/noncommunicable_diseases/en/. Accessed December 7, 2020; NA; NA; NA; NA; NA; NA; NA; R: A Language and Environment for Statistical Computing; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA","<jats:sec>
                  <jats:title>BACKGROUND</jats:title>
                  <jats:p>Large, randomized controlled trials (RCTs) are essential in answering pivotal questions in child health.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>METHODS</jats:title>
                  <jats:p>We created a bird’s eye view of all large, noncluster, nonvaccine pediatric RCTs with ≥1000 participants registered in ClinicalTrials.gov (last search January 9, 2020). We analyzed the funding sources, countries, outcomes, publication status, and correlation with the pediatric global burden of disease (GBD) for eligible trials.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>RESULTS</jats:title>
                  <jats:p>We identified 247 large, nonvaccine, noncluster pediatric RCTs. Only 17 mega-trials with ≥5000 participants existed. Industry funding was involved in only 52 (21%) and exclusively funded 47 (19%) trials. Participants were from high-income countries (HICs) in 100 (40%) trials, from lower-middle-income countries (LMICs) in 122 (49%) trials, and from both HICs and LMICs in 19 (8%) trials; 6 trials did not report participants’ country location. Of trials conducted in LMIC, 43% of investigators were from HICs. Of non-LMIC participants trials (HIC or HIC and LMIC), 39% were multicountry trials versus 11% of exclusively LMIC participants trials. Few trials (18%; 44 of 247) targeted mortality as an outcome. 35% (58 of 164) of the trials completed ≥12 months were unpublished at the time of our assessment. The number of trials per disease category correlated well with pediatric GBD overall (ρ = 0.76) and in LMICs (ρ = 0.69), but not in HICs (ρ = 0.29).</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>CONCLUSIONS</jats:title>
                  <jats:p>Incentivization of investigator collaborations across diverse country settings, timely publication of results of large pediatric RCTs, and alignment with the pediatric GBD are of pivotal importance to ultimately improve child health globally.</jats:p>
               </jats:sec>",NA,"0031-4005,1098-4275",NA,NA,NA,NA,"2021-09-01","3","148",NA,NA,NA
NA,"2020-11-30","2024-04-30",NA,"10.1101/2020.11.28.20240366","2024-05-01","2020-11-30","246","10.1101","Cold Spring Harbor Laboratory","18.229256","Crossref","26","26","8","Second versus first wave of COVID-19 deaths: shifts in age distribution and in nursing home fatalities","posted-content","http://dx.doi.org/10.1101/2020.11.28.20240366",NA,"http://orcid.org/0000-0003-3118-6859; http://orcid.org/0000-0002-2706-1730; NA; FALSE; FALSE; NA; John P.A.; Cathrine; Despina G.; Ioannidis; Axfors; Contopoulos-Ioannidis; first; additional; additional","https://syndication.highwire.org/content/doi/10.1101/2020.11.28.20240366; unspecified; vor; similarity-checking","2021012900100549000_2020.11.28.20240366v2.1; 2021012900100549000_2020.11.28.20240366v2.2; 2021012900100549000_2020.11.28.20240366v2.3; 2021012900100549000_2020.11.28.20240366v2.4; 2021012900100549000_2020.11.28.20240366v2.5; 2021012900100549000_2020.11.28.20240366v2.6; 2021012900100549000_2020.11.28.20240366v2.7; 2021012900100549000_2020.11.28.20240366v2.8; 2021012900100549000_2020.11.28.20240366v2.9; 2021012900100549000_2020.11.28.20240366v2.10; 2021012900100549000_2020.11.28.20240366v2.11; 2021012900100549000_2020.11.28.20240366v2.12; 2021012900100549000_2020.11.28.20240366v2.13; 2021012900100549000_2020.11.28.20240366v2.14; 2021012900100549000_2020.11.28.20240366v2.15; 2021012900100549000_2020.11.28.20240366v2.16; 2021012900100549000_2020.11.28.20240366v2.17; 2021012900100549000_2020.11.28.20240366v2.18; 2021012900100549000_2020.11.28.20240366v2.19; 2021012900100549000_2020.11.28.20240366v2.20; 2021012900100549000_2020.11.28.20240366v2.21; 2021012900100549000_2020.11.28.20240366v2.22; 2021012900100549000_2020.11.28.20240366v2.23; 2021012900100549000_2020.11.28.20240366v2.24; 2021012900100549000_2020.11.28.20240366v2.25; 2021012900100549000_2020.11.28.20240366v2.26; Williamson E , Walker AJ , Bhaskaran KJ , Bacon S , Bates C , Morton CE , et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020:2020.05.06.20092999.; Ioannidis JPA , Axfors C , Contopoulos-Ioannidis DG . Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environmental research. 2020;188:109890.; O’Driscoll M , Dos Santos GR , Wang L , Cummings DAT , Azman AS , Paireau J , et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020.; Ioannidis JPA . Precision shielding for COVID-19: metrics of assessment and feasibility of deployment. medRxiv. 2020:2020.11.01.20224147.; Gudbjartsson DF , Helgason A , Jonsson H , Magnusson OT , Melsted P , Norddahl GL , et al. Spread of SARS-CoV-2 in the Icelandic Population. The New England journal of medicine. 2020.; Comas-Herrera A , Zalakaín J , Lemmon E , Henderson D , Litwin C , Hsu A , et al. Mortality associated with COVID-19 in care homes: international evidence. Article in LTCcovid.org, International Long-Term Care Policy Network, CPEC-LSE, 14 October2020.; NA; Worldometers.info. COVID-19 CORONAVIRUS PANDEMIC Dover, Delaware, USA2020 [updated November 26, 2020. Available from: https://www.worldometers.info/coronavirus/#countries.; Comas-Herrera A , Zalakaín J , Litwin C , Hsu A , Lemmon E , Henderson D , et al. Mortality associated with COVID-19 in care homes: early international evidence. Article in LTCcovid.org, International Long-Term Care Policy Network, CPEC-LSE, 26 June 2020.; StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC; 2017.; NA; Salcher-Konrad M , Jhass A , Naci H , Tan M , El-Tawil Y , Comas-Herrera A. COVID-19 related mortality and spread of disease in long-term care: a living systematic review of emerging evidence. medRxiv. 2020:2020.06.09.20125237.; Horby P , Lim WS , Emberson JR , Mafham M , Bell JL , Linsell L , et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. The New England journal of medicine. 2020.; Axfors C , Schmitt AM , Janiaud P , van ‘t Hooft J , Abd-Elsalam S , Abdo EF , et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. medRxiv. 2020:2020.09.16.20194571.; The Atlantic Monthly Group. The COVID Tracking Project at The Atlantic: The Long-Term Care COVID Tracker. https://covidtrackingcom/data/long-term-care (Accessed 2021-01-21).; NA; NA; NA; Ministry of Health. COVID-19 Weekly Situation Report 29/06/2020 - 05/02/2020 Turkey. https://covid19.saglik.gov.tr/; 2020.; NA; Instituto Superiore di Sanità (ISS). Caratteristiche dei pazienti deceduti positivi all’infezione da SARS-CoV-2 in Italia. Dati al 11 november 2020. https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data; 2020.; Santé publique France. COVID-19. Point épidémiologique hebdomadaire du 12 novembre 2020. https://www.santepubliquefrance.fr; 2020.; Rijksinstituut voor Volksgezondheid en Milieu – RIVM. Epidemiologische situatie COVID-19 in Nederland, 10 november 2020, 10:00. https://www.rivm.nl; 2020.; Instituto Nacional de Salud. COVID-19 en Colombia. http://www.ins.gov.co/Noticias/Paginas/coronavirus-casos.aspx Accessed 2021-01-24.; Gobierno Digital Ministerio Secretaría General de la Presidencia, Ministerio del Interior y Ministerio de Ciencia Tecnología Conocimiento e Innovación. Cifras Oficiales COVID-19 en Chile: La Realidad Nacional en Datos. https://www.gob.cl/coronavirus/cifrasoficiales/ Accessed 2021-01-24.; Komite Penanganan COVID-19 Dan Pemulihan Ekonomi Nasional. Situasi virus COVID-19 di Indonesia. Peta Sebaran. https://covid19.go.id/peta-sebaran Accessed 2021-01-24.; NA; crossref; crossref; crossref; crossref; NA; publisher; NA; NA; NA; crossref; crossref; crossref; NA; NA; crossref; publisher; publisher; NA; crossref; NA; NA; NA; NA; NA; NA; NA; 10.1016/j.envres.2020.109890; 10.1038/s41586-020-2918-0; 10.1101/2020.11.01.20224147; 10.1101/2020.03.26.20044446; NA; 10.1136/bmj.m2063; NA; NA; NA; 10.1016/S2666-7568(20)30012-X; 10.1101/2020.06.09.20125237; 10.1101/2020.06.22.20137273; NA; NA; 10.1016/S0140-6736(20)32206-6; 10.1503/cmaj.201860; 10.1136/bmj.m3259; NA; 10.1111/eci.13423; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 1; NA; NA; NA; NA; 10259; NA; NA; NA; 12; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; e21; NA; NA; NA; NA; 1322; NA; NA; NA; e13423; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK; NA; NA; NA; NA; Experts criticise Australia’s aged care failings over COVID-19; NA; NA; NA; Global perspective of COVID-19 epidemiology for a full-cycle pandemic; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 1; NA; NA; NA; NA; 396; NA; NA; NA; 50; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 2020; NA; NA; NA; NA; 2020; NA; NA; NA; 2020; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; The Lancet Healthy Longevity; NA; NA; NA; NA; The Lancet; NA; NA; NA; European journal of clinical investigation; NA; NA; NA; NA; NA; NA","<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>OBJECTIVE</jats:title><jats:p>To examine whether the age distribution of COVID-19 deaths and the share of deaths in nursing homes changed in the second versus the first pandemic wave.</jats:p></jats:sec><jats:sec><jats:title>ELIGIBLE DATA</jats:title><jats:p>We considered all countries that had at least 4000 COVID-19 deaths occurring as of January 14, 2020, at least 200 COVID-19 deaths occurring in each of the two epidemic wave periods; and which had sufficiently detailed information available on the age distribution of these deaths. We also considered countries with data available on COVID-19 deaths of nursing home residents for the two waves.</jats:p></jats:sec><jats:sec><jats:title>MAIN OUTCOME MEASURES</jats:title><jats:p>Change in the second wave versus the first wave in the proportion of COVID-19 deaths occurring in people &lt;50 years (“young deaths”) among all COVID-19 deaths and among COVID-19 deaths in people &lt;70 years old; and change in the proportion of COVID-19 deaths in nursing home residents among all COVID-19 deaths.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Data on age distribution were available for 14 eligible countries. Individuals &lt;50 years old had small absolute difference in their share of the total COVID-19 deaths in the two waves across 13 high-income countries (absolute differences 0.0-0.4%). Their proportion was higher in Ukraine, but it decreased markedly in the second wave. The odds of young deaths was lower in the second versus the first wave (summary odds ratio 0.80, 95% CI 0.70-0.92) with large between-country heterogeneity. The odds of young deaths among deaths &lt;70 years did not differ significantly across the two waves (summary odds ratio 0.95, 95% CI 0.85-1.07). Eligible data on nursing home COVID-19 deaths were available for 11 countries. The share of COVID-19 deaths that were accounted by nursing home residents decreased in the second wave significantly and substantially in 8 countries (odds ratio estimates: 0.22 to 0.66), remained the same in Denmark and Norway and markedly increased in Australia.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>In the examined countries, age distribution of COVID-19 deaths has been fairly similar in the second versus the first wave, but the contribution of COVID-19 deaths in nursing home residents to total fatalities has decreased in most countries in the second wave.</jats:p></jats:sec>",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NA,"2024-03-25","2024-09-06",NA,"10.1101/2024.03.20.24304645","2024-09-07","2024-03-24","246","10.1101","Cold Spring Harbor Laboratory","18.175364","Crossref","37","37","0","Analyses of academician cohorts generate biased pandemic excess death estimates","posted-content","http://dx.doi.org/10.1101/2024.03.20.24304645",NA,"http://orcid.org/0000-0003-3118-6859; FALSE; John P.A.; Ioannidis; first","https://syndication.highwire.org/content/doi/10.1101/2024.03.20.24304645; unspecified; vor; similarity-checking","2024032700400638000_2024.03.20.24304645v1.1; 2024032700400638000_2024.03.20.24304645v1.2; 2024032700400638000_2024.03.20.24304645v1.3; 2024032700400638000_2024.03.20.24304645v1.4; 2024032700400638000_2024.03.20.24304645v1.5; 2024032700400638000_2024.03.20.24304645v1.6; 2024032700400638000_2024.03.20.24304645v1.7; 2024032700400638000_2024.03.20.24304645v1.8; 2024032700400638000_2024.03.20.24304645v1.9; 2024032700400638000_2024.03.20.24304645v1.10; 2024032700400638000_2024.03.20.24304645v1.11; 2024032700400638000_2024.03.20.24304645v1.12; 2024032700400638000_2024.03.20.24304645v1.13; 2024032700400638000_2024.03.20.24304645v1.14; 2024032700400638000_2024.03.20.24304645v1.15; 2024032700400638000_2024.03.20.24304645v1.16; 2024032700400638000_2024.03.20.24304645v1.17; 2024032700400638000_2024.03.20.24304645v1.18; 2024032700400638000_2024.03.20.24304645v1.19; 2024032700400638000_2024.03.20.24304645v1.20; 2024032700400638000_2024.03.20.24304645v1.21; 2024032700400638000_2024.03.20.24304645v1.22; 2024032700400638000_2024.03.20.24304645v1.23; 2024032700400638000_2024.03.20.24304645v1.24; 2024032700400638000_2024.03.20.24304645v1.25; 2024032700400638000_2024.03.20.24304645v1.26; 2024032700400638000_2024.03.20.24304645v1.27; 2024032700400638000_2024.03.20.24304645v1.28; 2024032700400638000_2024.03.20.24304645v1.29; 2024032700400638000_2024.03.20.24304645v1.30; 2024032700400638000_2024.03.20.24304645v1.31; 2024032700400638000_2024.03.20.24304645v1.32; 2024032700400638000_2024.03.20.24304645v1.33; 2024032700400638000_2024.03.20.24304645v1.34; 2024032700400638000_2024.03.20.24304645v1.35; 2024032700400638000_2024.03.20.24304645v1.36; 2024032700400638000_2024.03.20.24304645v1.37; publisher; publisher; NA; publisher; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; publisher; publisher; NA; publisher; NA; NA; publisher; publisher; publisher; publisher; publisher; publisher; publisher; publisher; crossref; crossref; publisher; publisher; publisher; publisher; publisher; publisher; 10.1111/eci.14008; 10.1111/padr.12475; NA; 10.1097/EDE.0000000000001723; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 10.1186/s12916-020-01632-8; 10.1073/pnas.2309557120; NA; 10.1136/bmjgh-2023-012646; NA; NA; 10.1093/eurheartj/ehac227; 10.1016/S0140-6736(24)00476-8; 10.1007/s10654-022-00853-w; 10.1016/j.envres.2022.114655; 10.3389/fpsyg.2022.971241; 10.3389/fpubh.2022.921196; 10.1183/09031936.00037808; 10.2807/1560-7917.ES.2019.24.14.1800118; 10.2139/ssrn.4449686; 10.1136/bmjopen-2022-066258; 10.1001/jamanetworkopen.2023.30877; 10.1038/s41598-023-42979-1; 10.1007/s10943-023-01899-0; 10.1007/s10943-021-01307-5; 10.1111/eci.13956; 10.1001/jamainternmed.2023.1547; NA; NA; New York Times (February 3, 2023), https://www.nytimes.com/interactive/2023/02/05/world/asia/china-obits-covid.html, last accessed March 11, 2024.; NA; Chinese Academy of Engineering, list of members, https://en.cae.cn/cae/html/en/col2229/column_2229_1.html, last accessed March 10, 2024.; Chinese Academy of Engineering, list of deceased members, https://www.cae.cn/cae/html/main/col56/column_56_1.html, last accessed March 10, 2024.; British Academy. Fellows of the British Academy, https://www.thebritishacademy.ac.uk/fellows/?order=year_elected#filtered-list, last accessed March 10, 2024.; British Academy. List of deceased Fellows, https://www.thebritishacademy.ac.uk/deceased-fellows/, last accessed March 10, 2024.; Royal Society. List of Fellows, https://royalsociety.org/fellows-directory/, last accessed March 12, 2024.; Royal Society. Search Past Fellows, https://catalogues.royalsociety.org/CalmView/personsearch.aspx?src=CalmView.Persons, last accessed March 18, 2024.; List of members of Academy of Athens, http://www.academyofathens.gr/el/members, last accessed March 18, 2024.; Database of Nobel Prize laureates, https://public.opendatasoft.com/explore/dataset/nobel-prize-laureates/table/?flg=en-us&disjunctive.category, last accessed March 14, 2024.; All Nobel Prizes, https://www.nobelprize.org/prizes/lists/all-nobel-prizes/, last accessed March 14, 2024.; List of Nobel laureates by country, https://en.wikipedia.org/wiki/List_of_Nobel_laureates_by_country, last accessed March 14, 2024.; WHO. Global health observatory data repository. Life tables by country. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/gho-ghe-life-tables-by-country, last accessed March 10, 2024; NA; NA; Members of Chinese Academy of Sciences, http://english.casad.cas.cn/mem/divsions/domap/, last accessed March 10, 2024.; NA; China population pyramid 2023, https://www.populationpyramid.net/china/2023/, last accessed March 8, 2024.; https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm, last accessed March 12, 2024.; NA; NA; NA; NA; NA; NA; NA; NA; Zahl PH , Hemström Ö , Johansen R , Mamelund SE . Mortality in Norway and Sweden during the COVID-19 pandemic 2020-22: A comparative study. J Infect Public Health. 2023 Nov 3:S1876–0341(23)00371-4.; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 11; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; e066258; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Time-varying risk of death after SARS-CoV-2 infection in Swedish long-term care facility residents: a matched cohort study; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 12; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; 2022; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; BMJ Open; NA; NA; NA; NA; NA; NA","<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Death data from cohorts of academicians have been used to estimate pandemic excess deaths. We aimed to evaluate the validity of this approach.</jats:p></jats:sec><jats:sec><jats:title>Study design and setting</jats:title><jats:p>Data were analyzed from living and deceased member lists from Mainland China, UK and Greece academies; and Nobel laureates (and US subset thereof). Samples of early elected academicians were probed for unrecorded deaths; datasets overtly missing deaths were excluded from further analyses. Actuarial risks were compared against the general population in the same country in respective age strata. Relative incidence risk increases in death in active pandemic periods were compared to population-wide pandemic excess death estimates for the same country.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Royal Society and Academy of Athens datasets overtly missed deaths. Pre-pandemic death rates were 4-12-fold lower in the Chinese Academy of Engineering (CAE) versus respective age strata of the Mainland China population. A +158% relative increase in death risk was seen in CAE data during the first 12-months of wide viral spread. Both increases (+34% in British Academy) and decreases (-27% in US Nobel laureates) in death rates occurred in pandemic (2020-22) versus pre-pandemic (2017-2019) years; point estimates were far from known excess deaths in the respective countries (+6% and +14%, respectively). Published excess death estimates for urban-dwelling Mainland China selectively analyzed CAE, but not another Chinese academy (Chinese Academy of Sciences) with half the pandemic death rates.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Missingness, lack of representativeness, large uncertainty, and selective analysis reporting make data from academy rosters unreliable for estimating general population excess deaths.</jats:p></jats:sec>",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Encyclopedia of Cryptography and Security","2011-10-27","2020-06-02",NA,"10.1007/978-1-4419-5906-5_267","2024-09-06","2011","297","10.1007","Springer US","18.175364","Crossref","3","3","2","DoS Pushback","book-chapter","http://dx.doi.org/10.1007/978-1-4419-5906-5_267","en","John; Ioannidis; first","http://link.springer.com/content/pdf/10.1007/978-1-4419-5906-5_267; unspecified; vor; similarity-checking","267_CR1_267; 267_CR2_267; 267_CR3_267; crossref; NA; crossref; Bellovin S (2003) The Security Flag in the IPv4 Header. RFC 3514, Internet Engineering Task Force, April 2003; Ioannidis J, Bellovin SM (2002) Implementing pushback: Router-based defense against DDoS attacks. In: Proceedings of Internet society symposium on network and distributed system security. San Diego, pp 6–8; Mahajan R, Bellovin SM, Floyd S, Ioannidis J, Paxson V, Shenker S (July 2002) Controlling high bandwidth aggregates in the network. Comput Commun Rev 32(3):62–73; 10.17487/rfc3514; NA; 10.1145/571697.571724; NA; 6; 62; NA; Implementing pushback: Router-based defense against DDoS attacks; NA; NA; J Ioannidis; R Mahajan; NA; 2002; 2002; NA; NA; 3; NA; NA; 32; NA; NA; Comput Commun Rev",NA,NA,NA,"363-365",NA,NA,"2011-01-01; 2011-01-01; tdm; vor; 0; 0; http://www.springer.com/tdm; http://www.springer.com/tdm","2011",NA,NA,NA,NA,"9781441959058,9781441959065"
"Lecture Notes in Computer Science,Financial Cryptography","2007-07-20","2019-05-01",NA,"10.1007/3-540-36504-4_20","2024-09-04","2003","297","10.1007","Springer Berlin Heidelberg","18.163633","Crossref","11","11","14","Fileteller: Paying and Getting Paid for File Storage","book-chapter","http://dx.doi.org/10.1007/3-540-36504-4_20",NA,"John; Sotiris; Angelos D.; Vassilis; Ioannidis; Ioannidis; Keromytis; Prevelakis; first; additional; additional; additional","http://link.springer.com/content/pdf/10.1007/3-540-36504-4_20; unspecified; vor; similarity-checking","20_CR1; 20_CR2; 20_CR3; 20_CR4; 20_CR5; 20_CR6; 20_CR7; 20_CR8; 20_CR9; 20_CR10; 20_CR11; crossref; publisher; publisher; crossref; crossref; crossref; NA; crossref; NA; crossref; crossref; Blaze, M., Ioannidis, J., Keromytis, A.D.: Offline Micropayments without Trusted Hardware. In: Proceedings of the Fifth International Conference on Financial Cryptography. (2001); Howard, J.H., Kazar, M.L., Menees, S.G., Nichols, D.A., Satyanarayanan, M., Sidebotham, R.N., West, M.J.: Scale and performance in a distributed file system. ACM Transactions on Computer Systems 6 (1988) 51–81; Whitehead, E.: World Wide Web Distributed Authoring and Versioning (Web-DAV): An Introduction. ACM StandardView 5 (1997) 3–8; Blaze, M., Feigenbaum, J., Ioannidis, J., Keromytis, A.D.: The KeyNote Trust Management System Version 2. Internet RFC 2704 (1999); Postel, J., Reynolds, J.: File Transfer Protocol. Internet RFC 959 (1985); Fielding, R., Gettys, J., Mogul, J., Frystyk, H., Berners-Lee, T.: Hypertext Transfer Protocol — HTTP/1.1. Internet RFC 2069 (1997); Sandberg, R., Goldberg, D., Kleiman, S., Walsh, D., Lyon, B.: Design and implementation of the sun network file system. In: Proceedings of the 1985 Summer Usenix Conference, Portland, OR (1985); Blaze, M.: A Cryptographic File System for Unix. In: Proc. of the 1st ACM Conference on Computer and Communications Security. (1993); Vahdat, A.: Operating System Services for Wide-Area Applications. PhD thesis, University of California, Berkeley (1998); Mazieres, D., Kaminsky, M., Kaashoek, M.F., Witchel, E.: Separating key management from file system security. In: Symposium on Operating Systems Principles. (1999) 124–139; Anagnostakis, K.G., Hicks, M.W., Ioannidis, S., Keromytis, A.D., Smith, J.M.: Scalable Resource Control in Active Networks. In: Proceedings of the Second International Working Conference on Active Networks (IWAN). (2000) 343–357; 10.1007/3-540-46088-8_2; 10.1145/35037.35059; 10.1145/253452.253458; 10.17487/rfc2704; 10.17487/rfc0959; 10.17487/rfc2068; NA; 10.1145/168588.168590; NA; 10.1145/319151.319160; 10.1007/3-540-40057-5_25; NA; 51; 3; NA; NA; NA; NA; NA; NA; NA; NA; NA; 6; 5; NA; NA; NA; NA; NA; NA; NA; NA; NA; J.H. Howard; E. Whitehead; NA; NA; NA; NA; NA; A. Vahdat; NA; NA; NA; 1988; 1997; NA; NA; NA; NA; NA; 1998; NA; NA; NA; ACM Transactions on Computer Systems; ACM StandardView; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; NA; Operating System Services for Wide-Area Applications; NA; NA",NA,NA,"0302-9743","282-299",NA,NA,NA,"2003",NA,NA,NA,NA,"9783540006466,9783540365044"
"SSRN Electronic Journal","2022-02-17","2022-02-17",NA,"10.2139/ssrn.4033819","2024-08-01","2022","78","10.2139","Elsevier BV","18.089054","Crossref","0","0","2","Estimating Conditional Vaccine Effectiveness","journal-article","http://dx.doi.org/10.2139/ssrn.4033819","en","John P.A.; Ioannidis; first",NA,NA,NA,NA,"1556-5068",NA,NA,"SSRN Journal",NA,NA,NA,NA,NA,NA,NA
